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1 Introduction 
Infections with the hepatitis C virus (HCV) are one of the leading causes of acute and 
chronic liver disease. HCV is distributed worldwide with an estimated 150 million 
people chronically infected, representing approximately 2-3 % of the world 
population. Every year 3-4 million people are newly infected with HCV, in developed 
countries mostly resulting from injection drug use. Following infection, approximately 
85-90 % of patients do not exhibit any symptoms. Though, in the majority of newly 
infected people the virus persist in the liver, leading to chronic HCV infection. People 
with persistent infection often show histological signs of liver inflammation associated 
with progressive liver disease, resulting in an increased risk of developing 
hepatocellular carcinomas. Hence, HCV infection is one of the main causes for liver 
transplantations and in addition, responsible for more than 350 000 deaths per year 
due to HCV-related liver diseases (WHO, 2012).  
The current treatment regimen for chronic HCV infections is based on a combination 
of pegylated interferon (pegIFN)-α and the nucleoside analogue ribavirin. 
Unfortunately, sustained virological response (SVR) is only reached in 50 % of 
treated patients, which largely depends on the HCV genotype. More recently, two 
protease inhibitors, telaprevir and boceprevir have been approved. These novel 
directly acting antiviral (DAA) drugs will clearly improve the sustained response rates, 
however, such novel therapies with protease inhibitors or other DAA can lead to the 
selection of resistant viral variants. In addition, HCV treatment is accompanied by 
severe side effects and extremely high costs. The novel treatment options are 
therefore restricted to areas with highly developed public health systems. Thus, 
development of an effective vaccine is still a major goal, but the high genetic 
variability of the virus makes vaccine development a challenging task. 
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1.1 Hepatitis C virus 
Initially identified in 1989 by immunoscreening of patient sera suffering from post-
transfusional non A-, non B-hepatitis (Choo et al 1989), the hepatitis C virus was 
classified as a member of the family Flaviviridae in the genus Hepacivirus. The 
enveloped virus is composed of an icosahedral particle of about 40-50 nm in 
diameter. The lipid envelope contains the envelope proteins E1 and the dimerized 
E2. The viral envelope surrounds the capsid containing the small ribonucleic acid 
(RNA) genome. 
 
1.1.1 The genome organization 
The HCV genome is composed of one single stranded RNA molecule of 9.6 kilo 
bases (kb) in length. The small, positive-sense RNA genome encodes a single open 
reading frame (ORF) of 3000 amino acids (Bartenschlager et al 1993) that is 
proteolytically processed by host and viral proteases into ten single proteins: core, 
E1, E2, p7, NS2, NS3, NS4A and NS4B and NS5A and NS5B (see figure 1.1). The 
ORF is uncapped and flanked by untranslated regions (UTR). Of those highly 
conserved regions, the 5’-UTR of 340 nucleotides contains the internal ribosome 
entry site (IRES), which initiates translation of the polyprotein (Tsukiyama-Kohara et 
al 1992). The polyprotein encoding region is followed at the 3’-end by a second UTR 
approximately 200 nucleotides in length. It contains a variable region and a highly 
conserved region necessary for replication (Yanagi et al 1999).  
 
1.1.2 HCV proteins 
After cleavage of the polyprotein by host and viral protease, the resulting proteins 
can be divided into structural proteins, i.e. core, envelope 1 and envelope 2, and non-
structural proteins (NS), i.e. NS2, NS3, NS4A, NS4B ,NS5A and NS5B (see figure 
1.1). Between structural and non-structural, an additional membrane protein p7 is 
located. The structural proteins and the p7 protein are processed by the 
endoplasmatic reticulum (ER) signal peptidases, whereas the non-structural proteins 
are cleaved by viral proteases, i.e. the NS2/ 3 protease and the NS3/ 4A serine 
protease (see figure 1.1).  
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Figure 1.1 Organization of the HCV genome. 
The HCV genome is flanked by 5’- and 3’-UTR. The 5’-UTR contains the IRES, initiating translation. The resulting 
polyprotein is cleaved into structural and non-structural proteins by host endoplasmatic reticulum signal peptidase 
(diamonds) or by viral NS2/ 3 and NS3/ 4A serine protease (flash). Modified from (Moradpour et al 2007). 
 
The N-terminal core protein is highly conserved and makes up the viral nucleocapsid. 
Core protein can bind viral RNA (Santolini et al 1994), in addition, it is assumed that 
core protein plays a role in hepatocarcinogenesis and steatosis hepatitis (Hope et al 
2002, Lerat et al 2002). 
Downstream of core protein, the two envelope proteins E1 and E2 are encoded. 
Envelope proteins are highly glycosylated, which differs among genotypes and play 
an important role in cell entry. In addition, envelope protein E2 contains two 
hypervariable regions HVR-1 and -2. Several studies analyzed the role of HVR-1 and 
-2 as a target for neutralizing antibodies. However, the constant selection for 
mutations in this region enables the virus to evade the immune system (Polyak et al 
1998, von Hahn et al 2007). Furthermore, it is assumed that HVR-1 regulates the 
binding of E2 to cluster of differentiation 81 (CD81) (Roccasecca et al 2003, Sklan et 
al 2009, Zeisel and Baumert 2009). 
P7 is a membrane-spanning protein located in the endoplasmatic reticulum. It is 
assigned to a group of proteins called viroporine, which are essential for ion channel 
formation that play an important role in virus infection (Griffin et al 2003), as well as 
particle assembly and release of infectious virions (Steinmann et al 2007).  
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Non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B are located in the 
C-terminal region of the polyprotein. They are responsible for several processes 
including viral replication and processing of the polyprotein.  
NS2 is a transmembrane protein and essential for the completion of the viral 
replication cycle. Together with the N-terminal domain of NS3, NS2 forms an auto 
protease that cleaves between NS2 and NS3 (Grakoui et al 1993, Hijikata et al 
1993). The NS3 genome region encodes for a protein with multifunctional activity. 
The NS3 N-terminal part has a serine protease activity, whereas the C-terminal part 
has NTPase/ helicase activity (Gallinari et al 1998). The NS4A polypeptide functions 
as a co-factor for the NS3 serine protease and the resulting complex is responsible 
for the cleavage of all remaining C-terminal proteins. In addition, the NS3/ 4A 
protease is the target for recently approved drugs (Lamarre et al 2003). The 3’-
encoded helicase is indispensable for cytoplasmic RNA replication (Gallinari et al 
1999, Moradpour et al 2003), although its exact function is not fully defined yet. 
One of the functions of NS4B is the formation of a membranous web that acts as a 
scaffold for the replication complex (Egger et al 2002). NS5A plays an important role 
in viral replication, modulation of cell signaling pathways (Reyes 2002) and interferon 
response (Macdonald et al 2004). The ability of NS5A to bind to RNA defined a new 
functional target for development of agents to treat HCV infection and a new 
structural class of RNA-binding proteins (Huang et al 2005).  
Among the essential non-structural proteins, the most important is the tail-anchored 
NS5B, the viral RNA-dependent RNA polymerase, crucial for the transcription of viral 
RNA. Due to the lack of proof-reading activity of the error prone RNA-dependent 
RNA polymerase, HCV mutates with high rates leading to the significant generation 
of viral variants or ‘quasispecies’ [reviewed in (Bowen and Walker 2005b), see 1.2]. 
Resulting from a ribosomal frameshift +1 in the N-terminal domain of core, the F-
protein or alternative reading frame protein (ARFP) is synthesized. Its function and 
antigenic properties are largely unknown, though the presence of anti-F antibodies 
was shown in sera of chronically infected patients indicating an antigenic relevance in 
chronic infections (Komurian-Pradel et al 2004). 
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1.1.3 Viral replication 
Analysis of the HCV replication cycle became possible when in vitro model systems 
were developed. The invention of subgenomic replicons and later the full-length 
HCVcc system offer adequate in vitro model systems to study molecular mechanisms 
of HCV replication and the development of antiviral drugs (Lohmann et al 1999). 
These replication systems were complemented by the HCV pseudoparticle system 
(HCVpp) that enables monitoring of HCV entry (Bartosch et al 2003, Hsu et al 2003). 
With these models, various receptors have been identified to interact with HCV 
cellular membrane receptors. It is assumed that binding to hepatocytes requires the 
interaction of E1 and E2 proteins with glycosaminoglycanes (GAG), dendritic cell-
specific intracellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), liver/ 
lymph node-specific intracellular adhesion molecules-3-grabbing non-integrin (L-
SIGN) as well as the binding to (very)-low-density lipoprotein ((V)LDL) receptor. After 
binding to the cell surface, viral entry requires binding to further molecules such as 
tetraspanin, CD81, scavenger receptor class B type 1 (SR-B1), and both tight 
junction components Claudin (CLDN)-1 and Occludin (OCLDN)-1 (Sabahi 2009). It is 
assumed that CLDN-1 and OCLDN-1 are both essential for viral entry (Chevaliez and 
Pawlotsky 2012, Pietschmann 2009).  
A hallmark of HCV is its narrow host range that is in part due to species determinants 
residing in the entry molecules CD81 and OCLDN-1 (Ploss et al 2009). This is one of 
the reasons why small animal models were not yet developed. 
 
HCV internalizes via pH-depended clathrin-mediated endocytosis followed by fusion 
within an acidic endosomal compartment [see figure 1.2, (Blanchard et al 2006, 
Coller et al 2009)]. Decapsidated genomic RNA serves as messenger RNA for the 
IRES-initiated translation into the polyprotein by recruiting viral, as well as cellular 
proteins (Honda et al 1999). At the ER membrane the polyprotein is processed into 
the three structural proteins, the viroporin p7 and the six non-structural proteins 
[(Moradpour et al 2007), see 1.1.2]. Replication is mediated by the NS5B polymerase 
(Gwack et al 1997). The replication complex is build by NS4B protein membranous 
web formation and associates viral proteins, host cellular components and nascent 
RNA (Egger et al 2002, Elazar et al 2004). The positive-sense RNA molecule serves 
as template for a negative-sense RNA intermediate form that is used as template for 
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the numerous production of positive-sense RNA strands that are used for protein 
translation or packing into virions (Bartenschlager et al 2004, Moradpour et al 2007). 
For infectious HCV particle formation, the newly synthesized RNA interacts with core 
protein (Shimoike et al 1999, Tanaka et al 2000), cytoplasmic lipid droplets and VLDL 
machinery (Bartenschlager et al 2011). However, the export and transfer of mature 
virions to neighboring cells still needs to be elucidated (figure 1.2).  
 
 
Figure 1.2 Schematic l i fecycle of HCV. 
(a) Virus binding and internalization, (b) cytoplasmic release and uncoating, (c) IRES-mediated translation and 
polyprotein processing, (d) RNA replication, (e) packaging and assembly, (f) virion maturation and release 
(Moradpour et al 2007).  
 
1.2 HCV genomes and the origin of quasispecies 
Analysis of the HCV RNA genome resulted in the classification of HCV into seven 
genotypes, which can be further classified into subtypes (Murphy et al 2007). These 
genotypes are characterized by at least 30 % divergence in nucleotide sequence. 
HCV genotypes (and subtypes) have evolved separately in different geographical 
regions and are distributed worldwide. The most common variants found in Western 
countries are genotype 1a, 1b, 2a-c and 3a. There is much greater diversity of HCV 
in certain regions of Sub-Saharan Africa and South Asia (Simmonds et al 2005). 
Genotype 4 is predominant in the Middle East and Africa. Genotype identification is 
clinically important, as for the current treatment regimen of pegIFN-α and ribavirin 
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genotypes 2 and 3 have increased SVR rates in comparison to genotypes 1 and 4 
(Hnatyszyn 2005).  
HCV replicates at very high rates, with about 1012 copies per day (Neumann et al 
1998). Due to the lack of proofreading activity of the RNA-dependent RNA 
polymerase, HCV and other RNA viruses mutate frequently (Holland et al 1982) with 
a mutation rate of approximately 1.4x10-4 base substitutions per genome site per 
infected cell (Bukh et al 1995, Sanjuan et al 2004). Given the high replication 
capacity, it is likely that at least 109 viral variants arise in each infected person 
multiple times daily (Guedj et al 2010), resulting in a quasispecies of multiple closely 
related but distinct variants. Variants harboring substitutions that are deleterious for 
viral replication are negatively selected and removed from the quasispecies. Upon 
transmission of HCV only few members of the quasispecies establish infection of the 
next host (Bull et al 2011). This so called bottleneck may be the consequence of 
selection of the most fit variant for viral entry and consequently early infection. In 
addition, there is increasing evidence that immune selection pressure by B and T 
cells results in the positive selection of immune escape mutations in the viral genome 
[reviewed in (Bowen and Walker 2005b)]. After transmission of quasispecies, a 
second bottleneck has been described that might arise from host immune selection 
pressure driven by B and T cells (Bull et al 2011). This phenomenon has also been 
described for other RNA viruses, like human immunodeficiency virus (HIV) (Bar et al 
2010, Boutwell et al 2010, Keele et al 2008). 
 
1.3 HCV pathogenesis 
1.3.1 Transmission of HCV 
HCV is most commonly acquired through exposure to infectious blood. Before the 
introduction of diagnostic screening methods, HCV was mainly transmitted through 
contaminated blood transfusion products. Approximately 10-20 % of patients who 
received multiple blood products seroconverted to anti-HCV positive. Nowadays, 
blood products in Germany can be considered as safe with only a minimal remaining 
risk for HCV infection. Unfortunately, screening methods are not the standard of care 
in all countries. Blood transfusions from unscreened donors and therapeutic 
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procedures remain the major cause of HCV transmission in developing countries. In 
developed countries, newly diagnosed HCV infections mainly result from needle 
sharing of injection drug users (IDU) (Alter 2002). In addition, the effect of other 
modes of transmission, like tattooing or acupuncture has been discussed (Shepard et 
al 2005). Perinatal transmission is the major cause of HCV acquisition in children, 
with a rate of mother-to-child transmission of 4-7 % in infected women with 
detectable viremia [reviewed in (Maheshwari et al 2008)]. Infection via breast feeding 
seems to be very unlikely.  
 
1.3.2 Course of disease 
In approximately 85-90 % of newly HCV infected patients the acute infection 
processes asymptomatic (figure 1.3) and is thus frequently not diagnosed. 
Interestingly, asymptomatic infection more frequently results in the establishment of a 
chronic infection (85-90 %), whereas spontaneous clearance is more frequently 
observed in patients with severe clinical signs of hepatitis and jaundice (Gerlach et al 
2003) in comparison to asymptomatic infections. The presence of jaundice might be 
an indicator for a successful host immune response by cytotoxic cells that lead to 
clearance of the virus. Acute HCV infection is often accompanied by symptoms of 
fatigue, myalgia, low-grade fever, nausea and vomiting.  
 
 
Figure 1.3 Outcome of HCV infection.  
Adapted from (Maheshwari et al 2008). 
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A chronic HCV infection is characterized by the detection of anti-HCV antibodies and 
HCV RNA in serum of infected patients for more than six months. Risk factors for 
developing a chronic infection include age at the time of infection, male gender, 
alcoholism and co-infection with hepatitis B virus (HBV) or HIV. During chronic HCV 
infection about 15-30 % of patients have progression to liver cirrhosis, of which 1-5 % 
are at risk to develop hepatocellular carcinomas (Afdhal 2004, Fattovich et al 1997, 
Poynard et al 1997, Thein et al 2008).  
 
1.3.3 Diagnosis 
HCV infection can be diagnosed via detection of antibodies against HCV by 
immunoassays (e.g. ELISA). Of note, seroconversion can be delayed in 
approximately 30 % at the onset of symptoms (Farci et al 1991), especially in 
immunocompromised patients. In addition, approximately 10 % of acutely infected 
might lose HCV-specific serological markers (Alter and Seeff 2000). Detecting viral 
nucleic acid represents the most sensitive method for the diagnosis of HCV infection. 
The detection limits vary between the different polymerase-chain reaction (PCR)-
based test and nowadays reach lower limits of detection of 10 IU/ mL with a 
specificity of 95 %.  
 
1.3.4 Antiviral therapy 
Over the past decade, the dual therapy using pegIFN-α plus ribavirin became the 
standard treatment for all genotypes in acute infections, resulting in a decline of liver 
transaminase levels to normal levels, as well as a decrease in viremia in about 90 % 
of treated patients. However, in chronic infections success and duration of this 
treatment regimen largely depends on the viral genotype. Upon treatment of 
genotype 2 and 3 infected patients, SVR is reached in about 80 %, in contrast to 
genotype 1 and 4 infected, where SVR is achieved in less than 40 % of patients.  
Recently, considerable progress has been made for the treatment of HCV infections. 
The increasing knowledge of the HCV lifecycle led to the development of direct 
acting antivirals. These include the new protease inhibitiors boceprevir and telaprevir, 
which have been approved in 2011. The addition of telaprevir or boceprevir to the 
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existing dual therapy resulted in a shorter time to achieve undetectable HCV RNA 
levels and markedly increased therapy success in genotype 1 infected patients 
(Berman and Kwo 2009, Jacobson et al 2011, Kwo et al 2010, McHutchison et al 
2009, Poordad et al 2011, Zeuzem et al 2011).  
 
1.4 The immune response during an HCV infection 
Effective immune responses, including the innate and adaptive immunity are 
essential to control an HCV infection. Though, in the majority of infections, the 
immune system is not able to control the virus, leading to persistent infections. This is 
mainly due to several strategies of HCV to evade innate and adaptive immune 
responses. 
 
1.4.1 The innate immune response 
The innate immune response represents the first line of defense in viral infections. An 
important role of the innate immune response in viral clearance is suggested by the 
genomic association between a single-nucleotide polymorphism (rs12979860) 
3 kilobases upstream of the IL28B gene, which encodes the type III interferon IFN-λ3 
and sponatenous control of HCV infection (Thomas et al 2009, Tillmann et al 2010). 
Studies by Thomas and colleagues revealed that the C/ C genotype strongly 
enhances resolution of HCV infection among individuals of both European and 
African ancestry, whereas studies by Tillmann and colleagues showed that women 
with the C/ T or T/ T genotype who did not develop jaundice had a lower chance of 
spontaneous clearance of HCV infection.  
 
HCV-infected hepatocytes trigger the earliest immune responses via recognition of 
viral constituents by cells of the innate immunity. Infected cells and cells of the innate 
immunity recognize pathogen-associated molecular patterns (PAMP) via pattern 
recognition receptors (PRR), like toll-like receptors (TLR) and intracellular helicases 
of the retinoic acid-inducible gene-I (RIG-I)-like receptor family, which lead to the 
subsequent production of type I interferons (IFN-α and -β) and possibly type III 
interferons (IFN-λ) by hepatocytes and plasmacytoid dendritic cells (pDC). Binding to 
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PRR lead to the induction of several signaling cascades, including the downstream 
activation of IFN-regulatory factor-3 (IRF-3) and NF-κB, which results in the 
subsequent production of type I IFN. Binding of newly synthesized IFN-α/ β to the 
common type I IFN receptor on the surface of the infected (autocrine) or 
neighbouring (paracrine) cells induces signaling via the Jak/ Stat pathway [reviewed 
in (Schindler and Plumlee 2008)] and transcription of interferon stimulated genes 
(ISG). Newly produced IFN induce an antiviral state in the liver and by this 
contributes to viral clearance (Li and Lemon 2013, Rehermann 2009).  
Notwithstanding, HCV has evolved numerous mechanisms to circumvent RIG-I- and 
TLR- signaling and ISG expression. Several contradicting pathways have been 
suggested by which HCV dysregulates or block the Jak/ Stat pathway [reviewed in 
(Thimme et al 2012)]. These include HCV core protein interference with suppressor 
of cytokine signaling 3 (SOC3) that lead to the inhibition of tyrosine phosphorylation 
of STAT-1 (Bode et al 2003) or an inhibition of ISG transcription by upregulation of 
the protein phosphatase PP2Ac (Duong et al 2004). Evidence suggest that HCV 
NS3/ 4A protease functions as an antagonist of virus-induced IRF-3 activation and 
IFN expression [reviewed in (Gale and Foy 2005)], which lead to an impairment of 
type I IFN production. Furthermore, it is assumed that HCV blocks interferon effector 
functions by inducing protein kinase R phosphorylation, which inhibits eukaryotic 
translation initiation factor eIF2α and attenuates ISG protein expression (Garaigorta 
and Chisari 2009). 
Despite the induction of type I interferons by hepatocytes and pDC, other cell types 
of the innate immunity play a central role in the control of HCV infections in the liver. 
The liver contains an unusual population of resident lymphocytes, among which 
natural killer (NK) cells and natural killer T (NKT) cells are found in increased 
numbers (30 % NK cells, up to 50 % NKT cells) relative to their proportions in 
peripheral blood and other organs (Crispe and Mehal 1996, Norris et al 1998), which 
can even increase in HCV infected livers [up to 90 % NK cells (Doherty and 
O'Farrelly 2000)]. 
NK cells are granular lymphocytes that play a central role in viral infections. The main 
function of NK cells is to lyse malignant or virally infected cells by secretion of 
cytoplasmic granules, Fas ligand-mediated apoptosis and antibody-dependent 
cellular cytotoxicity. NK cells (and NKT cells) are thought to release IFN-γ, which lead 
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to the noncytopathic inhibition of HCV replication (Guidotti and Chisari 2006). Genetic 
studies revealed an association between homozygosity for the inhibitory NK cell 
receptor killer immunoglobulin-like receptor 2DL3 (KIR2DL3) and its ligand the 
human leukocyte antigen-C1 (HLA-C1) group and viral clearance (Khakoo et al 2004, 
Knapp et al 2010, Romero et al 2008). HCV might escape NK cell mediated killing by 
cross-linking of CD81 on the surface of NK cells by HCV E2 protein, which lead to 
NK cell inhibition (Crotta et al 2002, Tseng and Klimpel 2002). 
 
1.4.2 The adaptive immune response 
There are numerous lines of evidence that the adaptive immunity plays an important 
role in shaping the outcome of an HCV infection. CD4+ T cells play a prominent role 
in viral clearance during the acute phase of infection and are associated with long-
term control of HCV infection (Gerlach et al 1999). In addition, CD8+ T cells are 
important in immune control of the virus, as accumulation of HCV-specific CD8+ T 
cells in the livers of infected chimpanzees was shown to be associated with the onset 
of hepatitis and a decrease in viral load (Thimme et al 2002). The importance of 
neutralizing antibodies in controlling HCV infection gain increasing interest, as 
evidence suggest that neutralizing antibodies contribute to HCV clearance and 
protect from reinfection [reviewed in (Fafi-Kremer et al 2012)]. 
 
1.4.2.1 Humoral immunity 
During acute infection, the humoral immune response is directed against epitopes 
within structural and non-structural components of the virus. However, the role of 
antibodies during HCV infection is not completely understood. Studies in 
immunocompromised, antibody-deficient patients showed that HCV can be cleared 
without humoral immune responses (Semmo et al 2006). Antibodies titers increase 
8-20 weeks after infection (Thimme et al 2002), though, the largest fraction of the 
produced antibodies has no antiviral activity. Just a small fraction of antibodies has 
neutralizing capabilities. These neutralizing antibodies are in principle able to inhibit 
virus binding, entry and uncoating. During chronic infection, the amount of cross-
reactive neutralizing antibodies, targeting multiple genotypes, increase, yet they fail 
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to clear the virus (Logvinoff et al 2004). Studies by Pestka and colleagues suggest a 
central role for neutralizing antibodies in the early phase of infection. In a 
homogenous cohort, development of neutralizing antibodies in the majority of 
patients who cleared the virus was described, whereas delayed induction was 
observed in patients that processed to chronic infection (Pestka et al 2007). The 
main target for neutralizing antibodies has been identified in the envelope proteins E1 
and E2, especially in HVR-1, which is important in virus binding and entry (Sabo et al 
2011). The high degree of genetic variability of this short region in the viral envelope 
protein is the product of humoral immune pressure by neutralizing antibodies. 
Continuous selection of escape mutations in targeted B cell epitopes is a key feature 
of chronic infection and one reason for the lack of sterilizing immunity against HCV 
(Osburn et al 2010, Ray et al 1999, von Hahn et al 2007). 
 
1.4.2.2 Cellular immunity 
CD4+ and CD8+ T cells recognize infected cells when they encounter antigen-
presenting cells (APC) displaying their cognate peptide antigen on major 
histocompatibility complex (MHC) class I or II molecules, respectively. T cell 
activation requires the interaction of T cell receptors (TCR) and peptide-MHC 
complexes and the interaction of ligand-receptor pairs providing costimulatory signals 
mediated by CD80 and CD86. Upon recognition of the cognate antigen complexed 
with MHC molecules CD4+ and CD8+ T cells start to produce proinflammatory 
cytokines interleukin (IL)-2, IFN-γ and tumor necrosis factor-α (TNF-α), if co-
stimulation is provided, which in turn activates cells of the immune system including 
macrophages. Activated CD8+ T cells can lyse infected cells via secretion of 
cytotoxic granules containing granzymes and perforin, resulting in Fas-mediated 
apoptosis of target cells. CD4+ T cells function to help B and T cell responses by 
promoting the activation of APC and by secreting cytokines and chemokines. 
 
While effector CD8+ T cells are particularly important in viral clearance, CD4+ T cells 
are absolutely necessary to provide CD8+ T cell help and play a role in long-term 
control of the virus. In a chimpanzee model, it was shown that antibody-mediated 
depletion of CD4+ T cells resulted in the inability of CD8+ T cells to control HCV 
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replication followed by the emergence of escape mutations in MHC class I-restricted 
epitopes (Grakoui et al 2003). Broadly directed HCV-specific CD4+ T cells are 
universally detectable during early stages of infection with a similar repertoire of 
targeted epitopes, regardless of outcome. Nevertheless, in chronically evolving HCV 
infection, HCV-specific CD4+ T cells show early functional defects and becomes 
completely undetectable within months (Schulze zur Wiesch et al 2012). In chronic 
HCV infection, CD4+ T cell responses are impaired, in the context of weak or even 
absent, dysfunctional CD4+ T cells, which might be associated with decreased IL-2 
amounts (Semmo et al 2005). In addition, increasing evidence suggest that 
regulatory T cells play a prominent role in HCV infections, by suppressing virus-
specific T cells in a contact-depended manner. It was shown that the amount of 
CD4+ CD25+ T cells is increased in chronic HCV infection, in comparison to patients 
that resolved the infection (Cabrera et al 2004). 
 
It is well accepted that the cell-mediated immunity, in particular, strong and sustained 
CD4+ and CD8+ T cells responses targeting multiple epitopes, is critical for HCV 
resolution [reviewed in (Bowen and Walker 2005a, Rehermann 2009, Thimme et al 
2012, Walker 2010)]. In contrast to other viral infections, the onset of cellular immune 
responses is delayed in HCV infections, starting 8-12 weeks after infection (Bowen 
and Walker 2005a, Rehermann 2009). Interestingly, the frequencies of HCV-specific 
CD8+ T cells are generally lower than those observed in other chronic infections, like 
Epstein-Barr virus (EBV) or HIV infection (Callan et al 1998, Ogg et al 1998). The 
increase in HCV-specific T cell responses coincides with the increase of 
transaminases and the onset of hepatitis.  
CD8+ T cells recognize their cognate antigens on peptide-MHC class I complexes 
and respond by killing the infected cells by cytolytic elimination and the secretion of 
antiviral cytokines to create an antiviral state. The importance of functional CD8+ T 
cell responses was shown in a chimpanzee model, where infected animals that lack 
CD8+ T cell responses were unable to control viremia until HCV-specific CD8+ T cell 
responses recovered (Shoukry et al 2003). 
Peptides for endogenous MHC class I-presentation to CD8+ T cells are generated in 
the cytosol of APC. When viral RNA or DNA enters the cell and replicates within it, 
the originating messenger RNA is transcribed into proteins in the cytosol. Part of the 
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proteins is subsequently degraded in proteasomes and transported through the 
transporter associated with antigen processing (TAP) complex into the 
endoplasmatic reticulum, where they are further trimmed to produce peptides of 8-10 
amino acids in length. The short peptides are assembled with MHC class I molecules 
and transported via the Golgi apparatus to the cell surface. The HLA class I molecule 
is composed of a β2-microgloblin light chain and the α heavy chain, which contains 
the two peptide-binding domains α1 and α2 and an immunoglobulin-like domain α3. 
The peptide binding groove of HLA class I molecules is, in contrast to HLA class II 
molecules, closed by the ends of the α helixes of the α1 and α2 domains. 
Consequently, the closed class I groove enchases shorter peptides. Naturally, an 
HLA class I molecule has six pockets, of which the second and the last pocket are 
particularly important in determining which peptide is bound [figure 1.4; reviewed in 
(Klein and Sato 2000)]. This results in a restriction in the amount of peptides that can 
bind with high affinity to particular HLA alleles. Antigen presentation is thus a 
sensitive mechanism with respect to variation in the peptide sequence. It was shown 
that mutations in HLA-restricted epitopes can result in the abrogation of antigen 
presentation of a particular epitope (Timm et al 2007).  
 
 
Figure 1.4 Schematic drawing of antigen-presentation to CD8+ T cells via HLA class I . 
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It has been highlighted in numerous studies that the CD8+ T cell response during 
HCV infection is relatively weak and dysfunctional. 
Dysfunctional or exhausted CD8+ T cells are not able to secrete antiviral cytokines or 
to proliferate in response to recognition of viral antigens. CD8+ T cell exhaustion is 
mainly due to the up-regulation of inhibitory receptors and ligands on the cell surface 
of CD8+ T cells or infected cells, respectively. Among those are the programmed cell 
death-1 (PD-1), which was shown to be up-regulated on HCV-specific CD8+ T cells 
of chronically infected patients (Golden-Mason et al 2007, Penna et al 2007, 
Radziewicz et al 2007). Dual up-regulation of PD-1 and cytotoxic T lymphocyte 
associated antigen-4 (CTLA-4), which structurally resembles and thus competitively 
inhibits the co-stimulatory CD28, on HCV-specific CD8+ T cells was observed in liver 
infiltrating lymphocytes, which were profoundly dysfunctional (Nakamoto et al 2008). 
Furthermore, T cell immunoglobin domain and mucin domain containing molecule-3 
(Tim-3) (Golden-Mason et al 2009), as well as the NK cell receptor 2B4 (CD244) 
(Schlaphoff et al 2011) has also been found to be up-regulated on HCV-specific 
dysfunctional CD8+ T cells. These finding strongly suggest that blockage of inhibitory 
receptor pathways represents a novel therapeutic strategy to restore HCV-specific 
CD8+ T cell function. 
Beyond progressive dysfunction of HCV-specific CD8+ T cells mutational escape 
also plays a role in viral immune evasion. The combination of the strong immune 
pressure exerted by cells of the adaptive immunity and the low fidelity viral RNA 
polymerase, results in the emergence of viral escape mutations during acute phase 
of infection, which is associated with viral persistence (Erickson et al 2001, Timm et 
al 2004). However, the emergence of escape mutations is associated with a 
decrease in viral fitness costs and a reduced replicative capacity of the virus, which is 
supported by studies of Timm and colleagues showing that the transmission of an 
HLA-B*08-associated escape mutation to an HLA-B*08-negative patient resulted in 
reversion of the mutation to the consensus sequence (Timm et al 2004). 
Nevertheless, factors regulating viral escape mutations are not fully identified. As 
already mentioned, CD4+ T cell help during acute phase of infection might play a role 
(Grakoui et al 2003). In addition, limited diversity of T cell receptors is discussed to 
be associated with the emergence of escape mutations (Meyer-Olson et al 2004).  
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HCV is characterized by high levels of genetic variation between genotypes and 
subtypes, but also between isolates of the same subtype. On the context of HLA-
allelic restriction, this high sequence diversity thus represents the main barrier for 
immune control. There is strong evidence for the association between particular HLA 
class I alleles and the outcome of infection. In a well-defined homogeneous cohort of 
women accidentally infected with HCV, HLA-A*03, -B*27 and -Cw*01 were 
associated with viral clearance, whereas HLA-B*08 was significantly associated with 
viral persistence (McKiernan et al 2004). Indeed, the protective effect associated with 
the presence of particular alleles can be limited to a certain HCV genotype. Studies 
indicate that the protective effect of HLA-B*27 is limited to HCV genotype 1 infection 
and does not expand to other genotypes, which was due to intergenotype sequence 
diversity of the immunodominant HLA-B*27-restricted epitope (Neumann-Haefelin et 
al 2010). Along with these findings, studies by Giugliano and colleagues analyzed the 
impact of genotype-specific sequence difference on the CD8+ T cell response in a 
cohort of injection drug users infected with genotype 1 and 3 and showed that the 
majority of CD8+ T cell responses were genotype-specific, indicating that sequence 
differences between genotypes are relevant at the epitope level (Giugliano et al 
2009). In line with this, HLA-B*57 was associated with viral clearance in a cohort 
where genotype 1a was the predominating circulating virus. In contrast, in another 
cohort where genotype 1b was the predominating circulating virus HLA-B*57 was not 
protective (Kim et al 2011). The same study provided evidence, suggesting that 
transmission of viral strains with pre-existing mutations in HLA-B*57 epitopes 
attenuates viral control and that epitope variants that are less recognized abrogate 
the protective effect of HLA-B*57. Thus even minor sequence variations in the same 
subtype can abrogate CD8+ T cell responses. 
 
1.4.3 Liver immunology 
As being a hepatotropic virus, the major site of HCV replication is the liver or more 
precisely hepatocytes. The immunology of the liver is unique as antigen-presentation 
in the liver can induce immunological tolerance. This is advantageous in case of liver 
transplantation [(Calne et al 1967), reviewed in (Calne 2000)], though it remains a 
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major problem in hepatotropic viral infections, like HCV or hepatitis B virus (HBV) 
infections.  
The microenvironment of the liver is characterized by the release of 
immunosuppressive mediators produced by both parenchymal and non-parenchymal 
cells, including IL-10, transforming growth factor-β (TGF-β) and prostaglandin E2 
(PGE2), which contribute to the tolerogenic environment. 
Liver-resident antigen-presenting cells include myeloid DC (mDC), pDC, liver 
sinusoidal endothelial cells (LSEC), hepatic stellate cells and hepatocytes. Each of 
those cell types contribute to tolerance induction by different strategies, which include 
the release of inhibitory cytokines, the expression of inhibitory molecules, like B7-H1 
by pDC, LSEC, hepatocytes and stellate cells, or the failure to provide co-stimulation 
[reviewed in (Thomson and Knolle 2010)]. 
Hepatocytes function as efficient antigen-presenting cells in vitro (Bertolino et al 
1998, Bertolino et al 1999), however, their role in antigen presentation in vivo has 
long been ambiguous. Hepatocytes are separated from the lumen of the sinusoid by 
a layer of fenestrated LSEC, making hepatocytes not easily accessible for circulating 
lymphocytes. Meanwhile, it was shown in mouse models that the combination of slow 
blood flow, the fenestrated endothelium and the lack of a basal membrane provide 
circulating lymphocytes access to hepatocytes through cytoplasmic extensions 
penetrating the endothelial fenestrations (Warren et al 2006). Nevertheless, CD8+ T 
cells primed by hepatocytes only undergo initial expansion, which is followed by 
clonal deletion due to BCL-2-interacting mediator of cell death (Bim) and caspase-
dependent apoptosis (Holz et al 2008). Furthermore, it was demonstrated that CD8+ 
T cells can enter hepatocytes by a mechanism of so called suicidal emperipolesis. 
This might represent a unique mechanism of CD8+ T cell deletion and a process that 
is critical for maintenance of tolerance (Benseler et al 2011). Taken together, 
hepatocytes, which represent the primary site for HCV replication and virus-specific 
CD8+ T cell recognition, might play a prominent role in the failure to control HCV 
infection. Though, the role of hepatocytes in tolerance induction in humans is not 
clarified yet. Unfortunately, the lack of a suitable small animal model hampers studies 
for the influence of hepatocytes in vivo.  
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1.5 Vaccination trials in HCV 
The development of a suitable vaccine to prevent chronic HCV infections still remains 
a major goal. Unfortunately, the high genetic variability of the virus makes vaccine 
design challenging. Indeed, 10-30 % of patients clear the virus and upon reinfection 
these patients have significantly increased rates of viral clearance in comparison with 
primary infections (83 % vs. 25 % in primary infection) (Osburn et al 2010). These 
results indicate that the induction of HCV-specific memory responses is possible and 
vaccine development reasonable.  
The current vaccination studies are mainly designed to elicit an adaptive immune 
response, as HCV clearance require immune responses mounted by HCV-specific 
cellular and humoral immunity. The effort that had been made in vaccine 
development so far can be divided in studies that aimed the induction of T cell 
responses targeting non-structural proteins, and those that target the induction of 
neutralizing antibodies against the envelope proteins E1 and E2. The lack of a 
suitable animal model additionally hampered the development of suitable vaccines. 
Most data that study the efficacy of therapeutic vaccination have to be obtained from 
the chimpanzee model.  
Examples for vaccine candidates that are in preclinical or early clinical development 
are shortly summarized in the following [reviewed in (Fauvelle et al 2013)]. Drane 
and colleagues developed a prototype vaccine with the HCV core protein and 
ISCOMATRIX adjuvant (HCV Core ISCOMATRIX vaccine), which has been shown to 
induce CD4+ and CD8+ T cell responses specific for the HCV core protein in animal 
models, as well as human studies. In a phase I placebo controlled study, antibody 
responses were detected in 23 out of 24 patients receiving different concentrations of 
the vaccine. CD8+ T cell responses specific for core peptides were detectable in 2 
out of 8 patients (Drane et al 2009).  
Another phase I placebo controlled study investigated the efficacy and safety of the 
HCV E1E2/MF59C.1 vaccine, containing the envelope proteins E1 and E2 and the 
adjuvant MF59C.1. Experiments revealed neutralizing antibodies, as well as CD4+ T 
cell responses specific for E1 and E2 but neutralizing antibody titers declined already 
16 weeks after the last vaccination (Frey et al 2010).  
Barnes and colleagues aimed to elicit HCV-specific T cells using recombinant 
adenoviral vectors expressing HCV non-structural proteins to achieve potential 
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protection in a phase I study of healthy human volunteers. Immunization with these 
vectors resulted in the induction of polyfunctional CD4+ and CD8+ T cells targeting 
multiple epitopes also across genotypes. Memory responses were detectable even 
one year after immunization (Barnes et al 2012). The latter study underlines the 
importance of the induction of broad and polyfunctional CD8+ T cell responses.  
Creating vaccines that elicit CD8+ T cell responses covering the genetic diversity of 
circulating isolates, as well as infecting quasispecies still seems to be a major 
obstacle. Indeed, it is not clear, whether a vaccine aimed to elicit a broad cross-
reactive response should contain several immunogens representing a bunch of viral 
targets and variants, or if it rather should contain less immunogens that are itself able 
to prime CD8+ T cells that are cross-reactive among viral quasispecies. 
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1.6 Aim of the study 
It has been highlighted in numerous studies that HCV-specific CD8+ T cells play a 
central role in viral containment, however, CD8+ T cell responses during HCV 
infection are relatively weak and dysfunctional. Activation of virus-specific CD8+ T 
cells is a complex process, in which, the sequence of the presented antigen, the site 
of initial antigen-encounter by CD8+ T cells has important consequences for the 
quality of the CD8+ T cell response. Thus, the aim of this study was to analyze 
determinants of HCV-specific CD8+ T cell expansion. 
HCV frequently evades adaptive immune responses by selection of escape 
mutations in MHC class I-restricted epitopes. These high variations in the viral 
genome make the development of a suitable vaccine challenging. An effective 
vaccine should induce CD8+ T cell responses that i) are polyfunctional with respect 
to effector mechanisms and ii) highly cross-reactive. Thus, it is of great importance to 
study the global sequence diversity of immunodominant CD8+ T cell epitopes and its 
impact on primary T cell responses.  
To study the impact of sequence differences in immunodominant epitopes on de 
novo immune responses, one aim of this dissertation was to establish a protocol for 
the priming and expansion of HCV-specific CD8+ T cells from the naïve T cell 
repertoire. The impact of the immunodominant HLA-A*02-restricted HCV NS31406-1415 
CD8+ T cell epitope on CD8+ T cell priming was analyzed. For this, the most 
frequent HCV NS31406-1415 sequence variants were selected from the HCV sequence 
database. The present study included in total five NS31406-1415 genotype 1b variants 
KLSGLGLNAV, KLSSLGLNAV, KLSALGLNAV, KLSALGVNAV and QLSGLGINAV, 
as well as two genotype 1a variants KLVALGINAV and KLVALGVNAV. In addition to 
the analysis of the priming potential, NS31406-1415-specific CD8+ T cells were analyzed 
for their potential to cross-react with other epitope variants and their polyfunctionality. 
To understand the nature of T cell receptors specific for the variants the individual 
TCR variable beta (Vβ) chain profiles used were assessed using a comprehensive 
antibody panel. 
 
A hallmark of chronic infections with hepatotropic viruses, such as HCV is the 
notoriously weak antiviral immune response by CD8+ T cells. As a hepatotropic virus, 
the main target and site of replication of HCV are hepatocytes. It is believed that the 
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liver-specific environment can induce tolerance of CD8+ T cells. Direct antigen 
presentation by virally infected hepatocytes thus might inhibit the CD8+ T cell 
response. Hence, the second aim of the study was to analyze the role of primary 
human hepatocytes on the activation of virus-specific CD8+ T cells, which may give 
important hints for the establishment of chronic infections by hepatotropic viruses. 
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2 Materials 
2.1 Chemicals and reagents 
Biocoll Separating Solution Biochrome 
CD14 MicroBeads Miltenyi Biotech 
CD45RO MicroBeads Miltenyi Biotech 
CD57 MicroBeads Miltenyi Biotech 
Dimethyl sulfoxide (DMSO) Roth 
Dulbecco's phosphate-buffered saline, 1X (PBS) Gibco 
Ethanol Sigma-Aldrich 
FACS-Clean Becton Dickinson 
FACS-Flow Becton Dickinson 
FACS-Rinse Becton Dickinson 
Intracellular (IC) Fixation Buffer  eBioscience 
Isopropanol Sigma-Aldrich 
Permeabilization Buffer (10X) eBioscience 
 
2.2 Cell culture media and additives 
anti-CD28/ CD49d Becton Dickinson 
anti-TGF-β antibody Becton Dickinson 
activin receptor-like kinase-5 (ALK-5) inhibitor  
(SB-431542) 
Sigma Aldrich 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
(HEPES) 1M  
PAA 
Brefeldin A Sigma Aldrich 
DNase I Roche 
Fetal bovine serum (FBS)  Biochrome 
GMP CellGro® DC CellGenixTM 
Granulocyte-macrophage colony-stimulating factor, 
recombinant human  
Peprotech 
Ham´s F12 + L-glutamine PAA 
human serum (HS), off the clot, type AB PAA 
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Interferon-γ, recombinant human Promokine 
Interleukin-1β, recombinant human Promokine 
Interleukin-15, recombinant human Peprotech 
Interleukin-2, recombinant human Roche 
Interleukin-21, recombinant human Peprotech 
Interleukin-4, recombinant human Peprotech 
Interleukin-7, recombinant human Peprotech 
Interleukin-6, recombinant human Peprotech 
Lipopolysaccharide (LPS) Sigma Aldrich 
Medium 200 + LSGS kit Invitrogen 
Non-essential amino acids (100X) PAA 
Penicillin/ streptomycin (100X) PAA 
Prostaglandin E2 Sigma Aldrich 
RPMI 1640 + L-glutamin  PAA 
Tryphan Blue  Gibco BRL/Invitrogen 
Trypsin/ EDTA (100X) PAA 
TNF-alpha, recombinant human Promokine 
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2.3 Cell culture media composition  
Table 2.1 Cell Culture media composition. 
Media Composition 
DC medium  GMP Serum-free Dendritic Cell Medium  
1 % HS 
40 U/ mL penicillin 
40 µg/ mL streptomycin 
Freezing medium FBS 
10 % DMSO 
human umbilical vein endothelial cells 
(HUVEC) 
Medium 200 
+ LSGS Kit (commercial); Invitrogen 
primary human hepatocytes DMEM/ Ham´s F12 
10 % FBS 
100 U/ mL penicillin 
100 µg/ mL streptomycin 
R10  
Peripheral blood mononuclear cells 
(PBMC) 
RPMI 1640 
10 % FBS 
10 mM HEPES  
100 U/ mL penicillin 
100 µg/ mL streptomycin 
T cell medium  GMP Serum-free Dendritic Cell Medium  
5 % HS 
40 U/ mL penicillin 
40 µg/ mL streptomycin 
 
2.4 Commercial kits 
CD8+ T Cell isolation kit, human Miltenyi Biotech 
Human IL-10 ELISA Kit  eBioscience 
Human/ mouse TGF-β1 ELISA Kit  eBioscience 
Human TGF-β1 ELISA Kit Promokine 
Monocyte isolation kit, human Miltenyi Biotech 
Qiamp DNA Blood Mini Kit   Qiagen 
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2.5 Peptides and MHC class I-multimers 
All peptides were synthesized by EMC microcollections. Peptides used for T cell 
priming had a purity of ≥ 95 %. CEF pool, Influenza A virus (Flu) and cytomegalovirus 
(CMV) peptide had a purity of ≥70 %.The lyophilized peptides were dissolved in 
DMSO to 20 mg/ mL and stored at -80 °C. Working solutions were further diluted with 
medium without supplements to a concentration of 1 mg/ mL and stored at -20 °C. 
All fluorescently labeled phycoerythrin (PE) MHC class I-dextramers were purchased 
from Immudex (Denmark) and were stored at 4 °C in the dark (peptides and 
dextramer are listed in table 2.2 and table 2.3, respectively). 
 
Table 2.2 Peptides. 
Name  
Sequence Protein Location Variant 
HLA-allele 
restriction 
p11 KLVALGINAV HCV NS3 1406-1415 gt 1a prototype HLA-A*02 
p42 KLSGLGLNAV HCV NS3 1406-1415 gt 1b consensus HLA-A*02 
p43 KLSALGLNAV HCV NS3 1406-1415 gt 1b Japan HLA-A*02 
p45 QLSGLGINAV HCV NS3 1406-1415 gt 1b Anti-D HLA-A*02 
p295 KLVALGVNAV HCV NS3 1406-1415 gt 1a escape HLA-A*02 
p301 KLSALGLNAV HCV NS3 1406-1415 gt 1b escape HLA-A*02 
p302 KLSALGVNAV HCV NS3 1406-1415 gt 1b Japan HLA-A*02 
p296 ALYDVVSKL HCV NS5B 2594-2602 gt 1a HLA-A*02 
p339 ALYDVVSTL HCV NS5B 2594-2602 gt 1b HLA-A*02 
CMV NLVPMVATV matrix protein 495-503  HLA-A*02 
Flu GILGFVFTL Influenza A 58-66  HLA-A*02 
CEF 
pool 
32 peptides 
CMV, EBV, 
Influenza 
--- --- 
defined 
HLA types 
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Table 2.3 MHC class I-dextramers. 
Name Sequence Protein Location Variant 
HLA-allele 
restriction 
p11 KLVALGINAV HCV NS3 1406-1415 gt 1a consensus HLA-A*02 
p42 KLSGLGLNAV HCV NS3 1406-1415 gt 1b consensus HLA-A*02 
p43 KLSALGLNAV HCV NS3 1406-1415 gt 1b Japan HLA-A*02 
p45 QLSGLGINAV HCV NS3 1406-1415 gt 1b Anti-D HLA-A*02 
p295 KLVALGVNAV HCV NS3 1406-1415 gt 1a escape HLA-A*02 
p301 KLSALGLNAV HCV NS3 1406-1415 gt 1b escape HLA-A*02 
p302 KLSALGVNAV HCV NS3 1406-1415 gt 1b Japan HLA-A*02 
p296 ALYDVVSKL HCV NS5B 2594-2602 gt 1a HLA-A*02 
p339 ALYDVVSTL HCV NS5B 2594-2602 gt 1b HLA-A*02 
CMV NLVPMVATV matrix protein 495-503  HLA-A*02 
Flu GILGFVFTL Influenza A 58-66  HLA-A*02 
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2.6 Antibodies for flow cytometry 
All antibodies used in this study were anti-human antibodies and stored at 4 °C. The 
concentrations applied for the antibodies utilized in this study can be seen in table 
2.4. 
 
Table 2.4 Fluorochrome conjugated antibodies for f low cytometry . 
Phycoerythrin (PE), allophycocyanin (APC), fluorescein isothiocyanat (FITC), peridinin chlorophyll protein 
(PerCP), cyanine (Cy), 7-Aminoactinomycin D (7-AAD). 
 
Antigen Conjugate 
Concentration; 
Dilution Company 
CD4 PE 0.2 mg/ mL; 
1:1000 
BD/ eBioscience 
 FITC 1:100 BD 
 PE-CF594 1:500 BD 
CD8 APC 1:1000 BD/ eBioscience 
 PerCP Cy5 1:400 eBioscience 
 Alexa700 
0.2 mg/ mL; 
1:100 eBioscience 
CD45RA PE 1:200 Miltenyi Biotech 
CD56 APC 1:100 BD 
CD107a PE 1:20 BD 
IFN-γ FITC 0.5 mg/ mL; 
1:1000 
eBioscience 
 PE-Cy7 1:500 eBioscience 
Interleukin-2 PerCP-eFluor710 0.012 mg/ mL; 
1:50 
eBioscience 
MIP-1β PE-Cy7 1:50 BD 
TNF-α APC 
0.2 mg/ mL; 
1:1000 eBioscience 
viability dye, fixable eFluor780 1:5000 eBioscience 
7-AAD PerCP 1:100 eBioscience 
V alpha 24 FITC  Beckman Coulter 
V beta 1 PE 1:200 Beckman Coulter 
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V beta 2 FITC 1:100 Beckman Coulter 
V beta 3 FITC 1:20 Beckman Coulter 
V beta 4 FITC 1:20 Beckman Coulter 
V beta 5.1 APC 1:100 eBioscience 
V beta 5.2 PE 1:10 Beckman Coulter 
V beta 5.3 APC 1:100 eBioscience 
V beta 7.1 PE 1:20 Beckman Coulter 
V beta 7.2 PE 1:100 Beckman Coulter 
V beta 8 eFluor450 1:500 eBioscience 
V beta 9 APC 1:100 eBioscience 
V beta 11 APC 1:20 Beckman Coulter 
V beta 12 FITC 1:20 Beckman Coulter 
V beta 13.1 FITC 1:100 eBioscience 
V beta 13.2 PE 1:100 eBioscience 
V beta 13.6 PE 1:20 Beckman Coulter 
V beta 14 PE 
FITC 
1:5 Beckman Coulter 
V beta 16 FITC 1:100 Beckman Coulter 
V beta 17 PE 1:20 Beckman Coulter 
V beta 18 PE 1:20 Beckman Coulter 
V beta 20 FITC 1:10 Beckman Coulter 
V beta 21.3 FITC 1:10 Beckman Coulter 
V beta 22 FITC 1:50 Beckman Coulter 
V beta 23 PerCP-eFluor710 1:50 
0.1 mg/ mL 
eBioscience 
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2.7 Consumables and equipment 
Cell culture flasks, T25, T75 Greiner Bio-One 
Cell culture inserts for 24-well plates,  
0.4 µm, translucent PET membrane 
BD Falcon™ 
Cell culture plates (6-, 12-, 24-, 48-, 96-well) Greiner Bio-One 
Centrifuge 5415C Eppendorf 
Centrifuge 5415R Eppendorf 
Collagen I 24-well multiwell plates BD BioCoat™ 
Cryo tubes, 2.0 mL Greiner Bio-One 
MidiMACS separator  Miltenyi Biotech 
MACS MultiStand Miltenyi Biotech 
Polystyrene round-bottom tubes, 5 mL  BD Falcon™ 
LeucosepTM tubes, 50 mL Greiner Bio-One 
LS-and LD-columns Miltenyi Biotech 
Megafuge 1.0R Heraeus 
Megafuge 40R Thermo Scientific 
Microscope TMS Nikon 
Microscope Primo Vert Zeiss 
Mr. Frosty freezing container  Thermo Scientific 
  
Flow cytometer  
FACS Calibur  Becton Dickinson 
FACS Canto II Becton Dickinson 
Navios flow cytometer Beckman Coulter 
2.8 Software and webpages 
FlowJo 7.6 Tree Star, Inc. 1997-2008 
GraphPad Prism GraphPad Software, Inc 
NCBI Homepage  http://www.ncbi.nlm.nih.gov/ 
Microsoft Office Microsoft 
Pestle VCR, NIH 
SPICE Nozzi/ Roederer 
Methods 
 
 
 31 
3 Methods 
3.1 Peripheral blood mononuclear cell isolation from buffy coats of healthy 
volunteer blood donors 
Buffy coats from healthy blood donors were obtained from the institute of transfusion 
medicine, university hospital Essen. For the isolation of peripheral blood 
mononuclear cells (PBMC) from buffy coats, first LeukosepTM tubes were equilibrated 
with 15 mL Percoll, a silica colloid density gradient medium with a density of 
1.077 kg/ L and spun down for one minute at 470xg. On the top of each filter, 30 mL 
of the blood product was carefully applied and centrifuged for 10 minutes at 1000xg. 
After centrifugation, the solution above the filter membrane containing the leukocytes 
was transferred to a new 50 mL Falcon tube. The LeukosepTM tube containing the 
remaining red blood cells and cell debris was discarded. PBMC were washed with 
45 mL PBS and additionally centrifuged for 8 minutes at 830xg. After discarding the 
supernatant the cell pellet was pooled in PBS and again centrifuged for 8 minutes at 
830xg. After these three purification and washing steps the cells could directly be 
used for cell culture or be dissolved in freezing medium, i.e. FBS containing 
10 % DMSO for freezing in liquid nitrogen. For freezing, the cells were placed in a 
Mr. Frosty freezing container containing 100 % isopropyl alcohol to gently cool the 
cells down by ~1 °C/ minute in a -80 °C freezer. After overnight freezing of the cells, 
the cells could now be placed in liquid nitrogen tanks.  
 
For these studies mainly PBMC from HLA-A*02-positive donors were required. 
Testing for the presence of HLA-A*02 molecules on the cell surface was performed 
using a fluorochrome-conjugated HLA-A*02-specific antibody. In brief, PBMC were 
resuspended in 10 µL PBS/ 1 % FBS containing 2 µL of anti-HLA-A*02 FITC 
antibody and incubated for 15 minutes at 4 °C. After washing, the cells were 
analyzed for the presence of HLA-A*02 by flow cytometry.  
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3.2 Thawing of PBMC for primary cell culture 
One vial of frozen PBMC was taken out of liquid nitrogen and quickly thawed in a 
37 °C water bath. Cells were taken up in 10 mL medium containing 1 mg DNase I. 
After three washing- and centrifugation steps (530xg, 7 minutes), the cell number 
was determined by counting in a Neubauer hemocytometer. Aliquots of the cell 
suspension were diluted with Tryphan blue stain and 10 μL of the diluted aliquot 
solution were transferred onto a Neubauer hemocytometer. Viable cells were counted 
and the number of cells per mL was calculated as follows: 
 
Number of cells/ mL = number of cells in the large square × dilution factor × 104 
 
After the last washing step, the cell pellet was resuspended in medium supplemented 
with the required cytokines or peptides and placed in cell culture plates or flasks at a 
concentration of 1.5x106 cells/ mL. Cells were cultured at 37 °C in humidified 
atmosphere containing 5 % CO2. Every 2-3 days the cells were fed with fresh 
medium containing cytokines and/ or growth factors.  
 
3.3 Intracellular cytokine staining for the detection of IFN-γ secretion 
For intracellular cytokine staining (ICS) 2x105 cells were seeded in a round bottom 
96-well plate, washed once with 200 µL medium without supplements and 
centrifuged for 5 minutes at 470xg. For the stimulation of IFN-γ secretion 100 µL 
medium (plus antibiotics and serum) containing 10 µg/ mL peptide were added to 
each well and incubated for 5 hours at 37 °C/ 5 % CO2 in the presence of 10 ng/ mL 
Brefeldin A. After incubation, the cells were washed with PBS and centrifuged for 
5 minutes at 470xg. All following centrifugation steps were performed with these 
parameters. For the staining of dead cells, fixable viability dye eFluor780 was diluted 
1:5000 in 100 µL PBS and applied to the cells for 20 minutes at 4 °C. After washing, 
fluorochrome-conjugated antibodies directed against CD4 and CD8 were added and 
incubated for another 15 minutes at 4 °C. After incubation the cells were washed and 
fixed using fixating solution for 20 minutes at 4 °C. Afterwards, the cells were washed 
once with 200 µL Permeabilisation buffer and centrifuged. Cells were stored 
overnight at 4 °C or directly stained with antibodies targeting intracellular structures 
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and molecules, like IFN-γ, which is trapped in the endoplasmatic reticulum. For 
intracellular staining of IFN-γ the cells were incubated with 0.5 mg/ mL anti-human 
IFN-γ FITC in 100 µL Perm buffer for 30 minutes at 4 °C. After washing, the cells 
were transferred in 5 mL Polystyrene tubes suitable for the application to flow 
cytometers. After fluorescent cytometry, data were evaluated using FlowJo software. 
For analysis, following gating strategy was applied: cells positive for the viability dye 
(dead cells) as well as CD4 positive cells were excluded by gating on negative cells, 
which are then further analyzed for the presence of CD8 and IFN-γ. Further statistical 
analysis was performed using GraphPad Prism software.  
 
3.4 Experimental setup for the priming of CD8+ T cells using monocyte-
derived dendritic cells 
3.4.1 Generation of monocyte-derived dendritic cells 
3.4.1.1 Isolation of CD14+ monocytes from PBMC 
For the enrichment of monocytes several technical capabilities are possible. In the 
present study, monocytes were isolated either by their ability to adhere to plastic or 
by magnetic cell separation (MACS), i.e. CD14+ MicroBeads or untouched isolation. 
The purity of the enriched cell fraction was determined by flow cytometry according to 
their location in a forward/ sideward scattered dot blot.  
 
3.4.1.1.1 Enrichment of monocytes by adherence to plastic  
For the isolation of monocytes, ~2x108 PBMC were thawed in 20 mL CellGro 
(0.4 % penicillin/ streptomycin). Cells were centrifuged for 4 minutes at 530xg and 
resuspended in 10 mL CellGro. Cell number was determined and the cells were 
incubated at a concentration of 2x107 cells/ well in 2 mL CellGro on a 6-well cell 
culture plate for 2-3 hours at 37 °C/ 5 % CO2. Monocytes were isolated by their ability 
to adhere to plastic. After incubation, the upper cell layer was carefully removed, 
while trying not to scratch the plastic surface. The remaining adhered cells 
represented the enriched monocyte fraction.  
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3.4.1.1.2 Isolation of CD14+ monocytes by magnetic cell separation 
For the isolation of monocytes by magnetic cell separation, two possible methods 
were applied. First, monocytes were isolated by direct labeling of CD14+ cells with a 
MicroBead-conjugated CD14-antibody. 
In brief, PBMC were thawed, washed and cell number was determined. 80 µL PBS/ 
1 % human serum (HS) and 10 µL CD14-MicroBeads per 107 were added to the cells 
and incubated for 15 minutes on ice. Afterwards, the suspension was filled up to 
5 mL and centrifuged for 5 minutes at 530xg. One LS column was rinsed with 
3 mL PBS/ 1 % HS. The cell pellet was resuspended in 0.5 mL PBS/ 1 % HS and 
applied onto the column. The column was washed three times with 3 mL 
PBS/ 1 % HS. The flow-through representing the unlabeled cells was discarded. To 
elute the bound CD14+ cells, the column was removed from the separator and 5 mL 
PBS/ 1 % HS were applied. Quickly, the plunger was pressed into the column and 
the CD14+ monocytes were collected.  
 
In addition, highly enriched unlabeled monocytes were obtained by depletion of the 
magnetically labeled cells using a cocktail of biotin-conjugated antibodies (i.e. 
anti-CD3-, anti-CD7-, anti-CD16-, anti-CD19-, anti-CD56-, anti-CD123- and anti-
glycophorinA-antibodies, representing T-, NK-, B- and dendritic cells and basophils) 
as well as anti-Biotin MicroBeads. In brief, 30 µL PBS/ 1 % HS, 10 µL FcR Blocking 
reagent and 10 µL Biotin-antibody cocktail per 107 cells were added to the cells, 
mixed well and incubated for 10 minutes at 4 °C. 30 µL PBS/ 1 % HS and 20 µL anti-
Biotin MicroBeads per 107 cells were added and incubated for additional 15 minutes 
at 4 °C. The cells were washed by adding 2 mL PBS/ 1 % HS and centrifuged. The 
cell pellet was resuspended in 500 µL PBS/ 1 % HS and isolation of unlabeled 
monocytes was achieved by depletion of the magnetically labeled cells as described 
above. 
 
3.4.1.2 Maturation of immature monocyte-derived dendritic cells  
After isolation the monocytes were differentiated into monocytes-derived DC (moDC) 
by the addition of 1000 U/ mL IL-4 and 800 U/ mL GM-CSF. After 48 hours, 
1.5 mL CellGro containing 1 % HS, 1000 U/ mL IL-4 and 1600 U/ mL GM-CSF were 
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added. The next day, non-adherent cells, representing immature moDC can be 
harvested and seeded at a concentration of 1-2x106 cells/ mL in 1 mL or 2 mL DC 
medium in a 12- or 6-well plate, respectively.  
In the present study, dendritic cells were either matured by a cytokine cocktail, i.e. 
1 µg/ mL PGE2, 10 ng/ mL IL-1β, 1000 U/ µL IL-6 and 10 ng/ mL TNF-α or a 
combination of 100 ng/ mL LPS and 100 U/ mL IFN-γ. Dendritic cells were matured 
overnight either in the presence or absence of the corresponding peptides, i.e. 
variants of the HCV NS31406-1415
 epitope at a concentration of 1 µg/ mL.  
Successful maturation of the dendritic cells was assessed by upregulation of the 
costimulatory molecules CD80 and CD86, as well as by microscopical appearance of 
dendritic cells, i.e. adherence, enlongated cell shape and the presence of dendrites.  
After overnight maturation, non-adherent cells representing immature dendritic cells 
were carefully removed and 2 mL cold PBS/ 1 % HS were added to the 6-well plate. 
After incubation for 30 minutes at 4 °C, dendritic cells were detached by 
resuspending. Large cells consisting of mature dendritic cells were counted. Because 
of few possible contaminating other cell types, e.g. NK cells and memory cells, the 
dendritic cells were irradiated with 30 Gy to avoid outgrowth. Irradiation was done at 
the institute of medical radiation biology at the university hospital Essen. 
 
3.4.2 Isolation of naïve CD8+ T cells from PBMC 
For CD8+ T cell isolation, CD8+ T Cell isolation kit was used according to 
manufactures instructions. In brief, PBMC were thawed as previously described (see 
3.2). After determining the cell number, 40 µL PBS/ 1 % HS and 10 µL CD8+ T cells 
biotin-antibody cocktail (containing biotin-labeled antibodies directed against CD4+ T 
cells, γ/ δ T cells, B cells, NK cells, dendritic cells, monocytes, granulocytes, and 
erythroid cells) were added per 107 cells and incubated for 5 minutes on ice. 30 µL 
PBS/ 1 % HS and 20 µL CD8+ T cells MicroBead-cocktail per 107 cells were added 
and incubated for 15 minutes on ice. Per 108 cells, one LS column was prepared by 
rinsing with 3 mL PBS/ 1 % HS. The cell suspension was applied onto the column 
and the unlabeled cell-containing flow-through, representing the enriched CD8+ T 
cells, was collected. The column was washed twice with 3 mL PBS/ 1 % HS. The 
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cells that attached to the magnetic column, representing the non-CD8+ T cells were 
discarded.  
After isolation of CD8+ T cells, CD57 positive cells, representing NK cell subsets and 
late stage effector CD8+ T cells, as well as CD45RO positive cells, representing 
activated and memory T cells were removed by depletion with specific antibodies. 
40 µL PBS/ 1 % HS and 10 µL CD57 and CD45RO MicroBeads per 107 cells were 
mixed with enriched CD8+ T cells and incubated for 15 minutes on ice. Afterwards, 
the cells were centrifuged for 4 minutes at 470xg. 500 µL of the cell suspension were 
applied onto the LD-column, which was previously rinsed with 3 mL PBS/ 1 % HS. 
After flow through of the cell suspension the column was washed 3 times with 
3 mL PBS/ 1 % HS. The flow through representing the naïve CD8+ T cell population 
was collected, washed and the cell number was determined. Naïve CD8+ T cells 
were incubated overnight in 3 mL CellGro containing 5 % HS and 5 ng/ mL IL-7. 
 
3.4.3 Co-culture of irradiated peptide-pulsed dendritic cells plus naïve CD8+ T 
cells 
Overnight cultures of naïve CD8+ T cells were harvested and counted. CD8+ T cells 
were adjusted to a concentration of 1x106 cells/ mL in CellGro.  
Irradiated dendritic cells were added at a ratio of 4:1 CD8+ T cells:DC with 4x105 
CD8+ T cells. The CD8+ T cell-DC suspension was centrifuged and resuspended in 
0.5 mL CellGro supplemented with 5 % HS and 30 ng/ mL IL-21 and placed in a 48-
well plate. For each peptide variant the co-culture was initiated in duplicate, if 
possible. After 72 hours, the cells were fed with 0.5 mL CellGro supplemented with 
5 % HS, 5 ng/ mL IL-7 and IL-15 and cells were subsequently fed every 2-3 days. To 
support cellular expansion, the cells were transferred to 12-well plates on day 5 of co-
culture and to 6-well plates on day 7.  
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3.4.4 Restimulation of co-culture  
After 10 and 19 days of co-culture, the cells were restimulated with either 
homologous peptide-pulsed PBMC or monocytes. When using peptide-loaded PBMC 
for restimulation, the cells were irradiated prior restimulation to avoid outgrowth of 
contaminating and inhibiting cells types.  
 
3.4.4.1 Restimulation of CD8+ T cell/ DC co-culture with autologous irradiated 
peptide-pulsed PBMC 
A maximum of 1x107 PBMC/ per well of co-culture was used for restimulation of the 
co-culture. PBMC were quickly thawed in 20 mL CellGro. The cells were centrifuged 
for 4 minutes at 530xg and resuspended in 10 mL CellGro. 1x107 cells were 
incubated at a concentration of 2x106 cells/ mL in T cell medium supplemented with 
the corresponding peptide at a final concentration of 1 mg/ mL. After incubation for 2-
3 hours at 37 °C/ 5 % CO2, the cells were washed twice and irradiated with 30 Gy. 
The co-culture was harvested and mixed with the irradiated, peptide-pulsed PBMC. 
After centrifugation, the cells were resuspended in 3 mL T cell medium. After 
48 hours, the cells were fed with T cell medium supplemented with 100 U/ mL IL-2 
and 5 ng/ mL IL-7 and IL-15 and were subsequently fed every 2-3 days.  
 
3.4.4.2 Restimulation of co-culture with autologous peptide-pulsed CD14+ 
monocytes 
For the restimulation with peptide-loaded monocytes, CD14+ monocytes were 
isolated by positive selection as described (see 3.4.1.1.2). 0.5x106 monocytes were 
pulsed with 1 µg/ mL of the corresponding peptide in 2 mL CellGro supplemented 
with 1 % HS, 1000 U/ mL IL-4 and 800 U/ mL GM-CSF at 37 °C/ 5 % CO2 overnight. 
The next day, the monocytes were harvested and mixed with the 10 or 19 day co-
culture, respectively and continued as described in 3.4.4.1.  
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3.4.5 Analysis of peptide-specific CD8+ T cells by MHC class I-multimer 
staining 
After 26 days of co-culture, cultured cells were analyzed for the presence of peptide-
specific CD8+ T cells, as well as their ability to cross-recognize the other variants. 
For dextramer staining, primed CD8+ T cells were harvested and the cell number 
was determined. 2x105 cells were transferred to a 96-well plate, washed with 200 µL 
PBS/ 1 % HS and centrifuged for 5 minutes at 470xg. 10 µL PBS/ 1 % HS containing 
1 µL of the corresponding dextramer were applied and cells were incubated for 
30 minutes at room temperature (RT) in the dark. After incubation, cells were washed 
with 200 µL PBS/ 1 % HS and centrifuged for 5 minutes at 470xg. For the surface 
staining, anti-CD8 APC antibody was diluted in PBS/ 1 % HS and incubated for 
20 minutes at 4 °C. After another washing step, 7-AAD PerCP was applied for 
10 minutes at 4 °C. The cells were transferred in 5 mL polystyrene tubes and 
analyzed by flow cytometry. 
 
3.4.6 Analysis of effector molecule production by intracellular cytokine 
staining for IL-2, TNF-α, IFN-γ, MIP-1β and the degranulation marker 
CD107a 
For intracellular cytokine staining, first CD14+ monocytes were isolated as described 
in 3.4.1.1.2 and pulsed with the corresponding peptides. For each well, 
1x105 monocytes were seeded and incubated with the peptides at a final 
concentration of 1 µg/ mL in 2 mL CellGro supplemented with 1 % HS, 1000 U/ mL 
IL-4 and 800 U/ mL GM-CSF at 37 °C/ 5 % CO2 overnight. The peptide-pulsed 
monocytes were used for the restimulation of CD8+ T cells the next day. 
The DC-primed CD8+ T cells were harvested and the cell number was determined. A 
total of 2x105 cells were transferred to the required number of wells on a 96-well 
plate. The cells were washed and supplemented with T cell medium containing IL-2, 
IL-7 and IL-15 as already described (see 3.4.4.1).  
The next day, peptide-pulsed monocytes were mixed with corresponding CD8+ T 
cells in T cell medium and incubated in the presence of 10 ng/ mL Brefeldin A and 
50 µL/ mL CD107a-antibody for 5 hours at 37 °C/ 5 % CO2. Table 3.1 shows an 
example of a 96-well plate used for ICS. 
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Table 3.1 Pipetting scheme for intracellular cytokine staining . 
monocytes 
+peptides 
 
Co-culture 
1 
unstim 
(-) 
2 
p11 
3 
p42 
4 
p43 
5 
p45 
6 
p295 
7 
p301 
8 
p302 
9 10 11 12 
A p11             
B p42             
C p43             
D p45             
E p295             
F p301             
G p302             
H             
 
After 5 hours of incubation, cells were centrifuged and washed with 200 µL PBS. For 
viability staining, cells were incubated for 20 minutes at 4 °C in 100 µL of fixable 
viability stain (-eFluor780). For surface staining, cells were incubated with anti-CD8 
Alexa700 and anti-CD4 PE-CF594 for 20 minutes at 4 °C. After incubation, cells were 
washed and centrifuged. For fixation, 100 µL IC Fixation Buffer was added and 
incubated for another 20 minutes at 4 °C. After fixation, the cells can be stored at 
4 °C overnight. For the staining of intracellular trapped cytokines, the following 
antibodies were used in 100 µL PBS/ 1 % HS for 30 minutes at 4°C: anti-IL-2 PerCP-
eFlour710, anti-TNF-a APC, anti-MIP-1β PE-Cy7 and anti-IFN-γ FITC. After 
intracellular staining, the cells were washed and resuspended in 200 µL PBS, 
transferred to 5 mL polystyrene tubes and analyzed by flow cytometry. Boolean 
gating was used to create a full array of all possible response patterns. Data were 
further analyzed using SPICE and Pestle software programs (by Mario Roederer and 
Joshua Nozzi, NIAID, NIH). 
 
3.4.7 Analysis of the peptide-specific T cell receptor V beta repertoire 
To further analyze the antigen specific T cell responses, we implemented a 
comprehensive antibody panel directed against individual variable beta (Vβ) chain 
TCR. The panel contained 27 different monoclonal antibodies which span 
approximately 70 % of the Vβ repertoire.  
For this purpose, 2x105 cells were stained simultaneously with antibodies against 
CD8 and IFN-γ and a set of 2-3 antibodies directed against TCR Vβ families as listed 
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in table 2.4. Most of the antibodies directed against TCR families were labeled with 
FITC, PE, or APC. CD8+ T cells responding to peptide restimulation were selected 
based on their IFN-γ secretion and further analyzed for their Vβ use using FACS 
Canto II.  
 
3.4.8 Analysis of the variant-specific avidities to the HLA-A*02 molecule 
Peptide binding studies were performed at the Sanquin Company in Amsterdam, the 
Netherlands. In brief, MHC class I-molecules are loaded with conditional ligands to 
form stable complexes. These ligands degrade during exposure to UV light, making 
the resulting empty MHC molecules suitable to be loaded with arrays of peptide 
ligands to determine MHC binding properties (Toebes et al 2006). 
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3.5 Primary human hepatocyte cultures 
Primary human hepatocyte (PHH) cultures were a kind regular gift from the 
department of gastroenterology and hepatology at the university hospital in Essen. 
The hepatocyte isolation procedure was carried out by a modified two-step 
collagenase perfusion technique and several Percoll centrifugation steps. The 
obtained hepatocytes were seeded on a collagen-I-coated 24-well plate and further 
purified by washing. Afterwards, the cells reached a ~90 % confluence with 
approximately 4x105 cells per well. The data of the patients used in this study are 
summarized in the appendix (see chapter 9). 
Before use, every hepatocyte culture was examined for their microscopically 
appearance, i.e. viability, number, polygonal shape, round prominent nuclei, 
contamination of other cell types and proliferation of fibroblastic cells. Before 
application, the cells were washed with medium. For all experiments DMEM/ Ham´s 
F12 medium, supplemented with 10 % FBS, 100 U/ mL penicillin and 100 µg/ mL 
streptomycin was used.  
 
3.5.1 Co-culture of PHH and PBMC 
Co-cultures of PHH and PBMC where accomplished in different compositions. If not 
stated different, 1.5x106 PBMC from healthy HLA-A*02 positive donors where used 
for the experiments. As viral model antigens, either the HLA-A*02-restricted Influenza 
M1 epitope (Flu) or CMVpp65 epitope (CMV) was used at a final concentration of 
1 µg/ mL. After 72 hours of co-culture, the cells were initially fed with fresh medium 
supplemented with 100 U/ mL IL-2 and 5 ng/ mL IL-7 and IL-15. Feeding was 
subsequently repeated every 2-3 days. After 7 to 10 days of co-culture, PBMC were 
harvested from the co-culture and used for MHC class I-multimer staining and/ or ICS 
for IFN-γ as already described in 3.4.5 and 3.3, respectively.  
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4 Results 
4.1 In vitro T cell priming of HCV-specific CD8+ T cells 
HCV is characterized by high levels of genetic variation between genotypes and 
subtypes but also between isolates of the same subtype. This enormous sequence 
diversity represents a major obstacle to vaccine design. Thus, it is of great 
importance to study the global sequence diversity of immunodominant CD8+ T cell 
epitopes and its impact on primary T cell responses. The obtained results will give 
important insights in the choice of effective sequences for vaccine design. 
 
In contrast to the expansion of memory T cell responses, the induction of primary T 
cell responses from naïve precursors in vitro requires contact between T cells and 
dendritic cells. As naïve T cells have more stringent activation and costimulatory 
requirements, the initial encounter of a peptide-MHC complex that is recognized by a 
specific T cell receptor will only result in full T cell activation (characterized by 
induction of activation markers, cytokine secretion, and proliferation) upon co-
stimulation provided by mature DC.  
 
4.1.1 Monocytes isolated by adherence to plastic are differentiated to dendritic 
cells 
To study the impact of sequence differences in immunodominant epitopes on de 
novo immune responses, one aim of this dissertation was to establish a protocol for 
the priming and expansion of HCV-specific CD8+ T cells from the naïve T cell 
repertoire. 
For in vitro CD8+ T cell priming, monocyte-derived dendritic cells (moDC) were used 
for the priming of naïve CD8+ T cells. Therefore, monocytes were enriched from 
PBMC from healthy HLA-A*02 blood donors (see 3.4.1.1). To analyze which strategy 
is optimal to enrich monocytes from PBMC, three different strategies were applied. 
The first approach was the isolation of CD14+ monocytes using CD14 MicroBeads 
followed by magnetic separation. The second magnetic separation approach 
included negative selection of CD14+ cells with MicroBeads directed against, e.g. 
CD4, CD8 and CD19 positive cells (monocyte isolation kit). The last method took 
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advantage of the ability of monocytes to adhere to plastic. The latter method 
represents a good way to isolate monocytes from PBMC, as the cells are untouched 
and are less stressed by staining and isolation protocols. Figure 4.1 shows 
representative dot plots comparing the three strategies.  
 
 
Figure 4.1 Different methods to isolate CD14+ monocytes. 
Monocytes were enriched by (A) adherence to plastic, (B) CD14+ MicroBeads, or (C) depletion of non-CD14+ 
cells using MicroBeads. Sideward scatter (SSC), forward scatter (FSC). 
 
Magnetic separation resulted in purities of 23.9 % monocytes when using positive 
selection and 38.3 % monocytes by depleting non-CD14+ cells (figure 4.1B and C). 
Monocytes isolated by adherence to plastic resulted in a purity of 20.8 % monocytes 
from total PBMC. Monocytes isolated by negative selection using the monocyte 
isolation kit (figure 4.1C) gave the highest purity in comparison to the other 
strategies. Monocytes isolated by positive section using CD14 MicroBeads were 
comparable in terms of purity (figure 4.1B), however, those cells have been coupled 
to antibodies/ MicroBeads, which might interfere with subsequent experiments. 
Monocytes isolated by their ability to adhere to plastic had lesser purities (figure 
4.1A) but are untouched and will be further purified in the following differentiation 
process to monocyte-derived dendritic cells. In addition, the latter approach 
represented the most sensitive and cost-effective isolation procedure and will be 
used for the generation of moDC throughout the study.  
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4.1.2 LPS/ IFN-γ-maturated dendritic cells upregulate the costimulatory 
molecules CD80 and CD86 
Primary stimulation with autologous peptide-pulsed dendritic cells is the most 
essential step in successful priming of CD8+ T cells. This implies that DC used for 
the initial stimulus have to be fully functional antigen-presenting cells with respect to 
upregulation of co-stimulatory molecules. In the current study, after differentiation of 
monocytes into dendritic cells with IL-4 and GM-CSF for 72 hours, the resulting 
immature monocyte-derived dendritic cells were matured either by the application of 
a cytokine cocktail containing PGE2, IL-1β, IL-6 and TNF-α, or by a combination of 
IFN-γ and LPS both for 24 hours (see 3.4.1.2). Figure 4.2A and B depict 
representative histograms showing the mean fluorescent intensity (MFI) of the CD80 
FITC antibody stained monocytes after maturation in comparison to immature cells. 
Figure 4.2C and D show examples of dot plots depicting the dual upregulation of 
CD80 and CD86 in LPS/ IFN-γ-matured moDC. Figure 4.2E and F show microscopic 
pictures of LPS/ IFN-γ matured DC. 
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Figure 4.2 LPS/ IFN-γ matured moDC upregulate CD80 and CD86 . 
MFI of CD80 FITC expression of (A) LPS/ IFN-γ-matured DC or (B) PGE2, IL-1β, IL-6 and TNF-α-matured DC. 
(C+D) Dual upregulation of CD80/ CD86 on LPS/ IFN-γ-matured DC. (E+F) Microscopic pictures of LPS/ IFN-γ-
matured DC at (E) 20x and (F) 10x magnification.  
 
As can be seen from figure 4.2A the stimulation with LPS/ IFN-γ for the maturation of 
DC led to a stronger upregulation of CD80 expression on DC (∆MFI, CD80-FITC=14.9, 
figure 4.2A) in comparison to stimulation with the cytokine cocktail (∆MFI, CD80-FITC=7.1, 
figure 4.2B). More important, LPS/ IFN-γ-matured moDC showed dual upregulation of 
CD80 and CD86 expression (68.3 % CD80+ CD86+ cells; figure 4.2D) in comparison 
to immature cells (26.2 % CD80+ CD86+ cells; figure 4.2C). In addition, LPS/ IFN-γ 
matured DC showed a typical morphology with extensive long dendrites when 
examined by light microscopy (figure 4.2E and F). 
Therefore, the LPS/ IFN-γ matured moDC resembled mature DCs with regard to 
immunophenotypic markers and microscopic appearance and were thus considered 
as being fully effective functional antigen-presenting cells suitable for the priming of 
naïve CD8+ T cells.   
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4.1.3 Isolated naïve CD8+ T cells have a high purity  
For the expansion of peptide-specific CD8+ T cells using mature moDC, isolated 
naïve CD8+ T cells were used. As the percentages of naïve CD8+ T cells vary 
significantly between donors, I chose to use normalized numbers of isolated naïve 
CD8+ T cells to keep the experimental conditions more similar. In addition, memory 
CD8+ T cells have a lower activation threshold, which can result in non-specific, 
cytokine-driven expansion of those cells. 
For the isolation of naïve CD8+ T cells, the CD8+ T cell isolation kit was used, 
followed by positive depletion of CD45RO (memory cells) and CD57 (NK-, activated 
cells) positive cells using MicroBeads for the respective antigens (see 3.4.2). In order 
to determine the purity of the enriched cell fraction, samples were taken after each 
isolation step and stained with antibodies directed against the following antigens: 
CD8, CD4, CD56 (NK cells) and CD45RA (naïve T cells). The dot plots depicted in 
figure 4.3 display the results of one representative experiment. After purification, only 
a few contaminating CD4+, CD56+ and CD45RA+ cells were present, resulting in a 
purity of CD8+ CD4- CD56- CD45RA+ T cells of ~71 %. Overall, the purity of the 
isolated naïve CD8+ T cells was sufficient for the application in the following 
experiments.  
 
 
Figure 4.3 Isolated naïve CD8+ T cells have a high purity . 
CD8+ T cells were isolated by depletion of non-CD8+ T cells followed by positive depletion of CD45RO+ and 
CD57+ cells. To determine the purity of the isolated CD8+ T cells, cells were stained with anti-CD8, anti-CD4, 
anti-CD56 and anti-CD45RA antibodies and analyzed by flow cytometry.  
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4.1.4 Restimulation of in vitro primed CD8+ T cells with irradiated, peptide-
pulsed PBMC results in increased expansion of specific CD8+ T cells 
For the initial priming, naïve CD8+ T cells were incubated with peptide-loaded mature 
moDC in a ratio of 4:1 in the presence of IL-21. IL-7 and IL-15 were added after 
72 hours (see 3.4.3). The expansion of antigen-specific CD8+ T cells requires 
multiple cycles of in vitro restimulation, due to the exceedingly low precursor 
frequency of T cells specific for a given antigen. For this purpose, cultures were 
restimulated using either homologous, peptide-pulsed monocytes isolated by 
magnetic separation or homologous, peptide-pulsed PBMC at day 10 and day 19 of 
co-culture (see 3.4.4). When PBMC were used for restimulation, cells had to be 
irradiated prior to restimulation in order to avoid outgrowth of e.g. NK cells. As 
positive control, a well-described HLA-A*02-restricted melanoma epitope was used. 
Those Melan-A-specific CD8+ T cells are readily detectable in the majority of HLA-
A*02-positive healthy individuals and in melanoma patients. Figure 4.4 depicts CD8+ 
dextramer+ T cells expanded with either the control peptide (HLA-A*02-restricted 
melanoma epitope; A and D) or the HCV-specific epitopes NS31406-1415
 (B and E) or 
NS31073-1082
 (C and F) and restimulated with peptide-loaded monocytes (A-C) or 
irradiated peptide-loaded PBMC (D-F). 
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Figure 4.4 Restimulation using peptide-pulsed PBMC resulted in increased expansion of 
peptide-specific CD8+ T cells . 
Expanded peptide-specific CD8+ T cells are shown after two rounds of restimulation using either (A-C) peptide-
pulsed CD14+ monocytes or (D-F) irradiated peptide-pulsed PBMC.  
 
Analysis of the dextramer positive cells after two rounds of restimulation revealed 
increased expansion of peptide-specific CD8+ T cells when using homologous, 
irradiated, peptide-pulsed PBMC (figure 4.4D-F) for the restimulation of the primed 
CD8+ T cells in comparison to the restimulation using peptide-pulsed monocytes 
(figure 4.4A-C). Using PBMC for the restimulation gave approximately 2-fold more 
peptide-specific CD8+ T cells in comparison to restimulation using monocytes 
(26.2 %, when using PBMS vs. 15.0 % when using monocytes for Melan-A peptide, 
2.33 % vs. 1.58 % and 1.74 % vs. 0.53 % for HCV peptides). Additionally, using 
PBMC for restimulation does not require monocyte isolation and thus represents a 
cost effective and time preserving method. 
 
To analyze the reproducibility of CD8+ T cell priming, naïve CD8+ T cells from five 
patients were primed with moDC and incubated in the presence of IL-21, IL-7 and 
IL-15 for 10 days (see 3.4.2). After restimulation with homologous, irradiated, 
peptide-pulsed PBMC the expansion of peptide-specific CD8+ T cells was analyzed 
using MHC class I-multimer staining (see figure 4.5).  
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Figure 4.5 Reproducible expansion of Melan-A-specific CD8+ T cells from five healthy blood 
donors throughout the culture period.  
Naïve CD8+ T cells were primed with moDC and incubated in the presence of IL-21, IL-7 and IL-15 for 10 days. 
Cultures were restimulated at day 10 and day 19 (red arrows) using homologous, irradiated, peptide-pulsed 
PBMC in the presence of IL-2. The expansion of peptide-specific CD8+ T cells was analyzed using MHC class I-
multimer staining.  
 
Figure 4.5 summarizes the results of five patients (in duplicate) used for the 
expansion of Melan-A-specific CD8+ T cells. The expansion of peptide-specific CD8+ 
T cells with two rounds of restimulation using peptide-loaded PBMC resulted in a 
continuous increase of peptide-specific CD8+ T cells throughout the culture period, 
yielding in average more than 50 % Melan-A-specific CD8+ T cells after 28 days.  
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4.1.5 Experimental setup for the priming of virus-specific CD8+ T cells  
In vitro priming of de novo HCV-specific T cell responses to viral antigens in healthy 
donors require the expansion of specific T cells from the naïve T cells repertoire, as 
the healthy blood donors were not exposed to the HCV antigens. In this study, we 
established a protocol for the expansion of antigen-specific CD8+ T cells from the 
naïve CD8+ T cell repertoire using an initial stimulation with peptide-pulsed IFN-γ/ 
LPS-matured dendritic cells, followed by two rounds of restimulation with 
homologous, peptide-pulsed, irradiated PBMC with the sequential use of IL-21, IL-7, 
IL-15 and IL-2 (see 3.4.3). The following figure (4.6) schematically outlines the 
established workflow for the generation of virus- (and tumor-) specific CD8+ T cells 
from the naïve CD8+ T cell repertoire. The established procedure was highly 
reproducible as demonstrated for the expansion of tumor-specific CD8+ T cells from 
healthy donors (figure 4.5). 
 
 
Figure 4.6 Experimental setup for the priming of virus -specific CD8+ T cells.  
Adapted from (Wölfl et al 2011). 
 
4.1.6 Most frequent HCV NS31406-1415 sequences  
After successfully establishing a protocol for the expansion of virus-specific CD8+ T 
cells from the naïve CD8+ T cell repertoire, the impact of the immunodominant 
HLA-A*02-restricted HCV NS31406-1415 CD8+ T cell epitope on CD8+ T cell priming 
was analyzed. 
Results 
 
 
 51 
For this, the most frequent HCV NS31406-1415 sequence variants were selected from 
the HCV sequence database (www.hcv.lanl.gov). The present study included in total 
five NS31406-1415 genotype (gt) 1b variants predominately circulating in Europe 
(KLSGLGLNAV and KLSSLGLNAV) and Japan (KLSALGLNAV and KLSALGVNAV), 
as well as an unique epitope sequence (QLSGLGINAV) originating from a large 
single-source outbreak (Wiese et al 2000). Viral sequence analyses in this cohort 
suggested strong selection pressure resulting in consistent mutational escape (Ruhl 
et al 2011). In addition, the most frequent genotype 1a sequence variants were 
studied (prototype: KLVALGINAV and variant: KLVALGVNAV). The genotype 1a 
prototype sequence is the most commonly used in human immunology studies of 
HCV infection for identification of HCV-specific CD8+ T cells. Table 4.1 summarizes 
the NS31406-1415 viral variants used in the present study.  
 
Table 4.1 Most frequent HCV NS3 1406-1415
 
sequence variants used for CD8+ T cell priming. 
 
4.1.7 Variant peptide-binding to HLA-A*02:01 molecule 
Peptide-MHC class I-complex recognition by cognate TCR is the molecular basis of 
antigen-recognition by CD8+ T cells. Each MHC allele has a distinct peptide-binding 
motif which favors certain amino acids in particular sequence positions. Amino acid 
substitutions in T cell epitopes thus can result in decreased peptide binding avidities 
to the HLA-A*02 molecule. To test potential differences in the binding avidity of the 
peptide variants used in this study to the HLA-A*02 molecule, peptide-binding assays 
to HLA-A*02:01 were performed at the Saquin company in the Netherlands, as 
already described elsewhere (Toebes et al 2006). 
Variant Genotype Sequence 
Frequency [%] [http://hcv.lanl.gov, 
(Yusim et al 2005)] 
gt 1a prototype gt 1a KLVALGINAV 43.3 
gt 1a variant gt 1a KLVALGVNAV 31.8 
Europe I gt 1b KLSGLGLNAV 42.8 
Europe II gt 1b KLSSLGLNAV 18.4 
Japan I gt 1b KLSALGLNAV 12.5 
Japan II gt 1b KLSALGVNAV 4.3 
Anti-D gt 1b QLSGLGINAV Anti-D cohort 
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Analysis of the peptide-binding to HLA-A*02:01 revealed no differences in binding 
avidities (figure 4.7). All peptides equally bind with high avidities to HLA-A*02:01. 
 
 
Figure 4.7 Peptide-binding avidit ies to HLA-A*02:01. 
All variants used in this study were analyzed for their specific binding avidity to the HLA-A*02:01 molecule as 
described in (Toebes et al 2006). 
 
4.1.8 HCV NS31406-1415 sequence variants show distinct priming potentials  
The most frequent HCV NS31406-1415 sequence variants (see table 4.1) were selected 
and used for the priming of naïve CD8+ T cells from healthy donors as summarized 
in 4.1.5, to study the impact of sequence differences on the priming capacity, cross-
reactivity, polyfunctionality and Vβ usage of CD8+ T cells. 
After 27 days of culture, NS31406-1415 expansion of peptide-specific CD8+ T cells was 
analyzed by MHC class I-dextramer staining (see 3.4.5) and IFN-γ production as 
described in 3.3. Figure 4.8 summarizes the results of eleven patients used for the 
expansion of HCV NS31406-1415 variant-specific CD8+ T cells.  
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Figure 4.8 Different epitope sequences show distinct priming potential.   
Primed virus-specific CD8+ T cells were expanded for 28 days and peptide-specific cells were analyzed by (A) 
peptide-specific MHC class I-multimers and (B) intracellular cytokine staining for IFN-γ. 
 
Primed NS31406-1415-specific CD8+ T cells were first analyzed using MHC class I-
multimer staining specific for the utilized NS31406-1415 variants (figure 4.8A). In 
addition, cells were analyzed for their effector function by staining for intracellular 
IFN-γ production (figure 4.8B). For analysis, cells were restimulated using monocytes 
pulsed with peptides representing the sequence of the epitope that was used for 
priming.  
Figure 4.8 shows that the different variants used for priming of CD8+ T cells exhibited 
distinct priming potentials. Overall one can conclude that genotype 1b variants 
exhibited better priming potential than genotype 1a variants. Interestingly, CD8+ T 
cells specific for the genotype 1a consensus sequence, as shown by MHC class I-
multimer staining (figure 4.8A), were not functional as they were not able to produce 
IFN-γ (figure 4.8B) and other cytokines (see figure 4.11). Importantly, the Japanese 
NS31406-1415 KLSALGLNAV variant rarely circulating in Europe had the best priming 
capacity (6 out of 11).  
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4.1.9 CD8+ T cells primed for the NS31406-1415 KLSALGLNAV variant have a 
high degree of cross-reactivity 
In addition to the analysis of the priming potential, NS31406-1415-specific CD8+ T cells 
were analyzed for their potential to cross-react with other epitope variants. For this 
purpose, monocytes were pulsed separately with all epitope variants and used for 
restimulation as described in 3.4.6. Cells that secrete IFN-γ above the threshold of 
0.5 % after background subtraction were considered as being cross-reactive. Figure 
4.9 shows an example of a cross-reactive CD8+ T cell response (upper panel) and 
an example of a CD8+ T cell response without cross-reactivity (lower panel). 
 
 
Figure 4.9 Primed peptide-specific CD8+ T cells show distinct cross-reactivity patterns.  
The expanded variant-specific CD8+ T cells (Upper panel: NS31406-1415 KLSALGLNAV, Lower panel: 
QLSGLGINAV) were analyzed by intracellular cytokine staining. Peptide variant-pulsed monocytes were used for 
the restimulation of virus-specific CD8+ T cells.  
 
CD8+ T cells expanded with the NS31406-1415 KLSALGLNAV peptide (1.88 % CD8+ 
IFN-γ+ cells) showed high degrees of cross-reactivity, as primed CD8+ T cells 
responded also to restimulation with other viral variants (i.e. KLSGLGLNAV 1.82 % 
CD8+ IFN-γ+, KLSSLGLNAV 1.73 % and QLSGLGINAV 1.94 %, figure 4.9, upper 
panel). In contrast, although CD8+ T cells primed against the anti-D variant 
(QLSGLGINAV) proliferated vigorously upon restimulation with the homologous 
variant (26.3 % CD8+ IFN-γ+ cells), they were not cross-reactive with other peptide 
variants (figure 4.9, lower panel).  
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Figure 4.10 summarizes the results of cross-reactivity testing of 11 patients used for 
the priming of HCV NS31406-1415-specific CD8+ T cells. It is important to mention that 
the NS31406-1415 KLSALGLNAV variant-primed CD8+ T cells were the most cross-
reactive T cells (figure 4.10C). CD8+ T cells primed against this peptide-variant 
frequently recognized other epitope variants. In contrast, CD8+ T cells primed with 
the NS31406-1415 QLSGLGINAV variant expanded in 4 out of 9 experiments, but were 
not cross-reactive with other variants (figure 4.10G). Despite the NS31406-1415 
KLSALGLNAV variant (figure 4.10C), the NS31406-1415 KLSSLGLNAV variant also was 
cross-reactive with other viral variants in 2 of 11 experiments and was thus 
considered as being cross-reactive as well (figure 4.10E). Genotype 1a sequences 
showed neither good priming potential nor cross-reactivity (figure 4.10A and D). 
 
 
Figure 4.10 Primed virus specific CD8+ T cells show distinct cross-reactivity patterns.  
After 28 days, the expanded virus-specific CD8+ T cells were analyzed by intracellular cytokine staining. Peptide 
variant-pulsed monocytes were used for the restimulation of virus-specific CD8+ T cells for 5 hours. IFN-γ 
secretion was analyzed by ICS. IFN-γ response above the set cut-off of 0.5 % CD8+ IFN-γ+ cells after 
background subtraction were considered as being cross-reactive. (A and D) Genotype 1a peptides, (B and C, E-
F) genotype 1b peptides.  
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4.1.10 NS31406-1415 KLSALGLNAV variant-primed CD8+ T cells are polyfunctional 
In addition to IFN-γ secretion, we examined polyfunctionality of primed CD8+ T cells 
in selected experiments, including the ability of variant-specific CD8+ T cells to 
simultaneously produce the effector cytokines and chemokines IFN-γ, IL-2, TNF-α 
and MIP-1β and to release cytotoxic factors by monitoring the expression of the 
degranulation marker CD107a after restimulation with homologous peptides (as 
described in 3.4.6). Peptide-specific CD8+ T cells were simultaneously stained with 
specific antibodies and analyzed by flow cytometry. Data were further analyzed using 
Pestle and SPICE software. Figure 4.11 (upper panel) depicts dot plots of one 
representative experiment showing examples CD8+ T cells producing these 
cytokines/ markers. Figure 4.11 (lower panel) displays pie-charts, illustrating the 
polyfunctionality of variant-specific CD8+ T cells, with respect to the number of 
different cytokines secreted.  
 
 
Figure 4.11 NS31406-1415 KLSALGLNAV variant primed CD8+ T cells are polyfunctional.  
After expansion of primed virus-specific CD8+ T cells for 28 days, cells were analyzed by intracellular cytokine 
staining for IFN-γ, TNF-α, IL-2, MIP-1β and CD107a. (Upper panel) Representative dot plots of the different 
stainings. (Lower panel) Pie charts of primed CD8+ T cells. Pie charts were generated using Pestle and SPICE 
software (blue= one function, green= two functions, yellow= three functions, orange= four functions and red= five 
functions).  
 
CD8+ T cells specific for the NS31406-1415 KLSALGLNAV variant were the most 
polyfunctional, as almost ¾ of the cells were able to produce more than three effector 
molecules. In contrast, cells specific for the NS31406-1415 KLSALGVNAV and the 
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genotype 1a NS31406-1415 KLVALGINAV variant had less polyfunctional CD8+ T cell 
responses. Most cells were able to secrete just one or two effector molecules. Thus, 
NS31406-1415 KLSALGLNAV primed CD8+ T cells had the best effector properties in 
comparison to CD8+ T cells specific for the other variants (see figure 4.11, lower 
panel). 
 
4.1.11 Limited TCR Vβs elicted by the NS31406-1415 QLSGLGINAV variant in 
contrast to the cross-reactive NS31406-1415 KLSALGLNAV variant 
To understand the nature of T cell receptors specific for the variant NS31406-1415 
QLSGLGINAV (good priming capacity; no cross-reactivity) versus the NS31406-1415 
KLSALGLNAV variant (very good priming capacity; good cross-reactivity), the 
individual TCR Vβ chain profiles used were assessed using a comprehensive 
antibody panel. Therefore, primed CD8+ T cells were restimulated with NS31406-1415 
QLSGLGINAV, KLSALGLNAV or KLSGLGLNAV variants. CD8+ T cells specific for 
the NS3 variants were selected based on IFN-γ secretion after restimulation and 
used for Vβ chain analysis (see figure 4.13). Figure 4.12 depict dot plots showing the 
percentages of IFN-γ secreting CD8+ T cells after restimulation.  
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Figure 4.12 Dot plots of expanded CD8+ IFN-γ+ virus-specific T cells used for Vβ chain 
analysis. 
After expansion of primed virus-specific CD8+ T cells for 28 days, cells were restimulated with NS31406-1415 
KLSALGLNAV, QLSGLGINAV and KLSGLGLNAV variants and analyzed by intracellular cytokine staining for 
IFN-γ. Non-restimulated expanded cells were used as background control. Responding cells were further 
analyzed for their Vβ chain repertoire (see figure 4.13). 
 
Figure 4.12 shows the results of the two patients used for the Vβ chain analysis. 
Patient 124 was either expanded with NS31406-1415 KLSALGLNAV or QLSGLGINAV 
(in duplicate) and patient 128 was expanded with NS31406-1415 QLSGLGINAV. As can 
be seen in figure 4.12, NS31406-1415 KLSALGLNAV primed CD8+ T cells were cross-
reactive with the KLSGLGLNAV variant, but (as expected) only to a minor extend 
with the QLSGLGINAV variant (Patient 124, first and second row). NS31406-1415 
QLSGLGINAV primed CD8+ T cells were not cross reactive at all, as expected (see 
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figure 4.10 and figure 4.12, Patient 124 expanded with QLSGLGINAV and Patient 
128). Figure 4.13 shows the Vβ chain analysis of the NS31406-1415 variant expanded 
cells. 
 
 
Figure 4.13 Limited T cell  receptor Vβ use for the QLSGLGINAV-primed CD8+ T cells.  
(A and B) Patient 124 in duplicate, (C) Patient 128. CD8+ T cells were restimulated with homologous or other 
NS31406-1415 peptide variants. Cells that were 7-AAD- CD4- CD8+ IFN-γ+ were analyzed with a panel of 24 
antibodies covering approximately 70 % of the TCR Vβ repertoire.  
 
After restimulation of primed CD8+ T cells with their homologous epitope variants, 
the TCRVβ profiles for NS31406-1415 KLSALGLNAV and QLSGLGINAV-specific CD8+ 
T cells showed variable profiles of TCR Vβ bias. CD8+ IFN-γ+ T cells primed with the 
KLSALGLNAV variant were characterized by a broader TCR Vβ use, namely Vβ1, -3, 
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-11, -20 and -22 (figure 4.13 panel A, black bars). In comparison, CD8+ IFN-γ+ T 
cells primed with the QLSGLGINAV variant were characterized by a more restricted 
use of TCR Vβ chains, i.e. solely Vβ3 and -5.1 for Patient 124 (figure 4.13, panel B, 
blue bars) and Vβ20 for Patient 128 (figure 4.13C, blue bars). When restimulating 
KLSALGLNAV-primed CD8+ T cells with the KLSGLGLNAV variant of NS31406-1415 
epitope, the same Vβ chains as for the homologous variant were utilized (figure 4.13, 
panel A, red bars). As expected, KLSALGLNAV-primed CD8+ T cells showed less 
cross-reactivity with the QLSGLGINAV sequence (see figure 4.9 and 4.10; figure 
4.13, blue bars).  
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4.2 Influence of primary human hepatocytes on the expansion of virus-
specific CD8+ T cells  
A hallmark of chronic infections with hepatotropic viruses such as HBV and HCV is 
the notoriously weak antiviral immune response by CD8+ T cells. It is believed that 
the liver-specific environment can induce tolerance of CD8+ T cells. Direct antigen 
presentation by virally infected hepatocytes thus might inhibit the CD8+ T cell 
response. Studying the role of primary human hepatocytes (PHH) on the activation of 
virus-specific CD8+ T cells may give important hints for the establishment of chronic 
infections by hepatotropic viruses.  
 
4.2.1 Characteristics of hepatocyte donors 
To study the influence of primary human hepatocytes on CD8+ T activation, liver 
tissue was dissected from patients undergoing surgery and PHH were isolated at the 
department of gastroenterology and hepatology, university hospital Essen. The 
patients included in this study represent a heterogeneous population with respect to 
age and gender (figure 4.14A), the presence of viral hepatitis (HCV or HBV, figure 
4.14B) and the type of surgery they underwent (figure 4.14C).  
 
 
Figure 4.14 Patient characteristics. 
(A) Age and gender, (B) type of surgery, (C) presence of viral infections. 
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4.2.2 PHH inhibit expansion of virus-specific CD8+ T cells in a contact-
dependent manner  
Before each experiment, the quality and purity of the PHH cultures was examined 
based on their microscopical appearance. Figure 4.15A shows an example of a 
freshly isolated PHH culture. Fresh hepatocytes had a polygonal shape, round 
prominent nuclei and showed little proliferation of fibroblastic cells.  
 
 
Figure 4.15 PHH inhibit the expansion of virus -specific CD8+T cells in vitro . 
(A) Light microscopic picture of a freshly isolated PHH monoculture. Expansion of virus-specific CD8+ T cells in 
the presence of PHH is assessed using MHC class I-multimer staining (B) or intracellular IFN-γ staining (C+D) 
after 7-10 days. Normalized mean, *** p<0.001. 
 
In the first set of experiments, the influence of PHH on the expansion of virus-specific 
CD8+ T cells was examined. For this purpose, co-cultures of PHH and PBMC were 
established. 1.5x106 PBMC were incubated with approximately 0.4x106 PHH in the 
presence of viral peptides (see 3.5). Next, PBMC were harvested from co-cultures 
and analyzed by MHC class I-multimer staining. Analysis of the dextramer positive 
CD8+ T cells after 7-10 days of co-culture revealed a reduced expansion of antigen-
specific CD8+ T cells in the presence of PHH (figure 4.15B).  
In addition, the number of IFN-γ secreting cells was significantly reduced as shown in 
figure 4.15C and D. The mean reduction of IFN-γ secretion after co-culture was 
approximately 75 % in several independent experiments. 
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It was first addressed, if the inhibitory effect required the contact between MHC-
peptide complexes on the hepatocytes with their specific TCR. For this purpose, we 
used hepatocytes from an HLA-A*02 negative donor, which were not able to present 
the HLA-A*02-restricted peptides. Figure 4.16A summarizes the results of two 
independent experiments. There was no difference in inhibition between HLA-A*02 
positive and negative donors, indicating that an antigen-specific contact was not 
necessary to mediate inhibition. 
In further experiments, we analyzed the role of soluble factors secreted by the 
hepatocytes per se in mediating inhibitory effects. For this, medium transfer 
experiments were performed. The supernatant of a 24 hour PHH or PBMC mono- or 
co-culture was used in increasing concentrations for the culture of freshly thawed 
PBMC in the presence of viral antigens. Figure 4.16B depict the normalized mean of 
three independent experiments performed. The supernatant of a PHH monoculture 
had a mild inhibitory effect on the expansion of virus-specific CD8+ T cells (60 % 
response compared to control). The supernatant of PBMC monocultures or PBMC/ 
PHH co-cultures similarly showed a mild inhibitory effect (minimum 75 % response 
compared to control). 
The results in figure 4.16B indicate that soluble factors released by hepatocytes per 
se or exhaustion of nutrients only marginally played a role and did not completely 
explain the drastic reduction in the number of antigen-specific T cells in the presence 
of hepatocytes seen in figure 4.15D. 
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Figure 4.16 PHH inhibit in a contact dependent manner.  
(A) PHH from HLA-A*02 negative donors were co-cultured with PBMC in the presence of HLA-A*02-restricted 
viral peptides. (B) The supernatant of a 24 hour PBMC, or PHH mono- or co-cultures was used in increasing 
concentrations for the culture of freshly thawed PBMC. (C) PBMC were grown in a membrane insert. (A-C) After 
7-10 days of culture, PBMC were harvested and analyzed by intracellular IFN-γ staining. Bars represent the 
normalized means in comparison to PBMC monocultures (ANOVA; p<0.001). 
 
Membrane inserts are commonly used in co-cultures to evaluate cell behavior in the 
absence of cell-cell contact. In order to determine if the inhibitory effect of PHH on 
CD8+ T cells depends on contact between PBMC and hepatocytes, transwell 
experiments were performed. On top of the hepatocytes a membrane insert with 
0.4 µm pore size was placed and 1x106 PBMC were seeded inside the membrane 
insert in the presence of viral antigens. In this experimental setup, PBMC and PHH 
share the same medium, but are not able to make physical contact. The results of the 
transwell experiments are depicted in figure 4.16C. The reduction in IFN-γ secreting 
cells was less pronounced in the transwell system (mean: 62.3 % response 
compared to control) and was similar to the effect when PHH-conditioned medium 
was used (figure 4.16B). In line with previous experiments the inhibitory effect was 
more pronounced when PBMC and PHH had physical contact (mean: 26.3 % 
response compared to control), indicating that physical contact between hepatocytes 
and PBMC was required to mediate the full inhibitory effect.  
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4.2.3 The inhibitory effect is hepatocyte specific 
To confirm that the inhibitory effect was specific for PHH and did not represent a 
culture artifact, human umbilical vein endothelial cells (HUVEC) were purchased as a 
control and incubated with peptide-pulsed PBMC. After 7 days of co-culture, virus-
specific CD8+ T cell expansion was verified by intracellular cytokine staining for 
IFN-γ and compared to PBMC monocultures. 
Indeed, the presence of HUVEC in the co-culture system did not lead to a decrease 
in the expansion on virus-specific CD8+ T cells (figure 4.17A). 
In addition, the role of a potential influence of the allogenic reaction, as PBMC and 
PHH are isolated from different patients, was excluded by a mixed-lymphocyte 
reaction. PBMC from two different patients were co-incubated with viral antigens for 
7 days and the frequency of IFN-γ producing cells was assessed. As control, PBMC 
from both patients were incubated separately. From figure 4.17B we can conclude 
that the allogenic background has no additional influence on the PHH/ PBMC co-
culture.  
 
 
Figure 4.17 Inhibitory effect is hepatocyte specific .  
(A) Human umbilical vein endothelial cells were co-cultured with PBMC and viral peptides for 7 days. (B) PBMC 
from two different patients were co-cultured in the presence of viral antigens. After 7 days of culture, PBMC were 
harvested and analyzed by intracellular IFN-γ staining. Bars represent the normalized means in comparison to 
PBMC monocultures.  
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4.2.4 Increased TGF-β level in the supernatant of PHH/ PBMC co-cultures 
To verify the influence of potential proinflammatory or inhibitory cytokines in the 
supernatant, after 72 hours of co-culture, the supernatant of the PHH and PBMC 
mono- and co-cultures was harvested and analyzed for the presence of different 
inhibitory or pro-inflammatory cytokines. The concentration of IL-2, TNF-α, IFN-γ and 
IL-10 was determined by Luminex technology at the institute of medical microbiology, 
university hospital Essen. The amount of TGF-β in the supernatant was determined 
by ELISA. Figure 4.18 depicts the results of the Luminex data. As can be seen, there 
was a slight increase in the cytokines IL-2 and IFN-γ in the presence of hepatocytes 
which might be due to the allogenic activation of the PBMC. Unexpectedly, no 
difference in the level of the inhibitory cytokine IL-10 could be detected (figure 4.18). 
 
 
Figure 4.18 Cytokine profi le in the supernatant of a PHH/ PBMC co -culture.  
After 72 hours, the supernatant from PBMC monocultures or PHH/ PBMC co-cultures was analyzed for the 
presence of IL-2, IFN-γ, TNF-α and IL-10 using Luminex technology. 
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TGF-β is an important immunomodulatory cytokine that can inhibit differentiation of 
effector T cells. TGF-β is produced by various liver cell populations, including 
hepatocytes and thus might play a role in CD8+ T cell tolerance induction. 
 
 
Figure 4.19 Increased TGF-β concentrations in PHH/ PBMC co-cultures.  
(A) The concentration of TGF-β was verified in the supernatant of a 3 or 10 days co-culture. (B) RhTGF-β was 
added in increasing concentrations to PBMC. After 7 days virus-specific CD8+ T cell expansion was analyzed. 
 
Soluble TGF-β in the supernatant was about 7-fold increased in PHH/ PBMC co-
cultures in comparison to TGF-β secretion by hepatocytes or PBMC monocultures 
after 3 days and about 4-fold increased after 10 days of co-cultures (figure 4.19A).  
To confirm that the concentrations of TGF-β determined by ELISA are indeed able to 
cause inhibition (see figure 4.13 and 4.14) we artificially added rhTGF-β in increasing 
concentration to PBMC cultures.  
Figure 4.19B depicts the results of four independent experiments. We could observe 
increasing inhibition of the CD8+ T cell response by increasing rhTGF-β 
concentrations and with an IC50 of approximately 1200 pg/ mL, the inhibitory effect 
caused by TGF-β fits to the concentration determined by ELISA. 
 
4.2.4.1 TGF-β blocking/ neutralization  
In order to confirm the participation of TGF-β in the induction of inhibition in PHH/ 
PBMC co-cultures, several strategies were applied to block or neutralize TGF-β-
mediated effects. The first approach included repeated application of an anti-TGF-β 
neutralizing antibody. A second approach was to block TGF-β in the co-cultures by 
Results 
 
 
 68 
the application of Follistatin. Follistatin is a compound that blocks the mode of action 
of members of the TGF-β superfamily by binding and neutralizing them.  
Last, the activin receptor-like kinase (ALK)-5 inhibitor (SB-431542) was applied to the 
co-cultures. ALK-5 is a part of the TGF-β type 1 receptor, thus blocking ALK-5 
inhibits TGF-β mediated signaling (Inman et al 2002). Hepatocytes where pre-
incubated with different concentrations of ALK-5 inhibitor ranging from 1 to 
1000 µM/ mL, before adding 1.5x106 PBMC plus 1 µg/ mL peptide. Figure 4.20 
summarizes the results. 
 
 
Figure 4.20 TGF-β blocking.  
TGF-β blocking/ neutralizing was assessed using the following reagents in PHH/ PBMC co-cultures: 0.1, 0.5 or 
1 µg/ mL Follistatin, 0.1 µg/ mL anti-TGF-β antibody, 1, 5, 50, 500 µM/ mL ALK-5 inhibitor. After 7 days of culture, 
PBMC were harvested and analyzed by intracellular IFN-γ staining. Bars represent the normalized means in 
comparison to PBMC monocultures.  
 
Unfortunately, none of the molecules applied to the PHH/ PBMC co-cultures were 
able to reverse the PHH-mediated inhibition of CD8+ T cell expansion. In one 
experiment the application of 1 µM/ mL ALK-5 inhibitor could reverse the inhibitory 
effect, however, this was not reproducible.  
Thus, the possible contribution of TGF-β in this system could not be confirmed and 
needs to be further elucidated.  
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5 Discussion 
5.1 In vitro priming of HCV-specific CD8+ T cells  
Chronic viral infections, like those caused by the Hepatitis C virus still remain a major 
health problem. An estimated 150 million people worldwide are chronically infected 
with HCV and are at high risk to develop steatosis and liver cirrhosis, resulting in an 
increased risk of developing hepatocellular carcinomas. The high rate of chronicity in 
HCV infected patients is mainly due to the impairment of the host immune system to 
control the viral infection. Due to the error prone viral polymerase, HCV frequently 
evades CD8+ T cell immune responses by substitutions in MHC class I-restricted 
epitopes. Mutations located in the HLA-binding anchors of an epitope (position two 
and the C-terminal amino acid for most HLA class I alleles) attenuate peptide binding, 
whereas mutations in the centre of the epitope more often result in impaired TCR 
recognition of the HLA class I/ peptide complex (Soderholm et al 2006). Moreover, 
beyond impairment of peptide affinity or TCR avidity substitutions inside epitopes or 
in the epitope flanking region can alter processing of the viral antigens. The high 
mutation rate of the virus is the key aspect in the failure to develop an effective 
vaccine. Due to the fact that 20-25 % can spontaneously clear the virus associated 
with a vigorous T cell response and importantly associated with a lower likelihood of 
persistent infection upon reexposure (Osburn et al 2010), the induction of memory T 
cell responses that provide at least partial protection should in principle be feasible. 
Unfortunately, due to the lack of a suitable model, trials to study the efficacy of 
different vaccines in humans are difficult. Thus, surrogate measures for vaccine 
efficacy are needed. In vitro T cell priming for the study of de novo T cell responses 
represents a tool to study the impact of antigen sequence variations on vaccination 
efficacy. Moreover, such in vitro generated HCV-specific T cells could also be utilized 
to treat HCV-reinfection after liver transplantation.  
In this study, we analyzed the role of minor sequence differences in an HLA-A*02-
restricted immunodominant CD8+ T cell epitope located in NS3 and the outcome of 
sequence differences on priming capacity and the induction of polyfunctional, cross-
reactive CD8+ T cell responses. We identified one epitope variant (NS31406-1415 
KLSALGLNAV) mainly circulating in Japan, which was more potent in the induction of 
effective CD8+ T cell responses in comparison to the other variants analyzed. 
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5.1.1 In vitro T cell priming 
To study the impact of sequence substitutions in the immunodominant HLA-A*02-
restricted NS31406-1515 epitope on the de novo induction of NS31406-1515-specific CD8+ 
T cells, we established an in vitro CD8+ T cell priming model. For this purpose, naïve 
CD8+ T cells were enriched from PBMC and stimulated with monocyte-derived 
dendritic cells. Models to reliably generate antigen-specific T cell responses in vitro 
are useful to screen candidate epitopes for vaccination trials. However, in contrast to 
the expansion of effector memory CD8+ T cells, the expansion of virus-specific CD8+ 
T cells from the naïve repertoire is elaborate.  
In this study, monocytes were isolated by adherence to plastic and differentiated in 
the presence of IL-4 and GM-CSF. Resulting moDC were matured with LPS/ IFN-γ, 
loaded with the epitope variants and used for the stimulation of naïve CD8+ T cells. 
Numerous studies have aimed at optimizing cytokine combinations and the duration 
of the stimulation for the maturation of DC including TNF-α and IL-1β, LPS and CD40 
ligand (Cella et al 1999), PGE2, IL-1β, IL-6 and TNF-α (Jonuleit et al 1997) and LPS/ 
IFN-γ (Vieira et al 2000, Wölfl et al 2011). In the present study, LPS/ IFN-γ-matured 
DC showed in contrast to PGE2, IL-1β, IL-6 and TNF-α-matured DC an upregulation 
of the costimulatory molecules CD80 and CD86 (see figure 4.2).  
The reason to use purified naïve CD8+ T cells relies on the lower activation threshold 
of memory CD8+ T cells, which might result in the unspecific expansion of those cell 
types. In addition, the amount of naïve T cells decreases with age and thus varies 
significantly between individuals (Ginaldi et al 1999). Due to the exceedingly low 
numbers of HCV-specific T cells in the naïve repertoire (Schmidt et al 2011), HCV-
specific CD8+ T cells need to be restimulated for expansion, using either peptide-
pulsed monocytes or peptide-pulsed, irradiated PBMC on day 11 and day 19. Both 
strategies were suitable for the expansion of antigen-specific CD8+ T cells, though, 
the use of irradiated PBMC seemed to be more effective, especially for the expansion 
of virus-specific CD8+ T cells. In addition, the use of PBMC represents the more time 
and cost effective strategy.  
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5.1.2 NS31406-1415-specific CD8+ T cells have distinct priming potential 
To analyze the impact of minor sequence differences in immunodominant CD8+ T 
cell epitopes, seven variants of the HLA-A*02-restricted NS31406-1415 epitope were 
selected [see table 4.1, HCV database, http://hcv.lanl.gov (Yusim et al 2005)]. These 
included the five most frequent genotype 1b variants KLSGLGLNAV (42.8 % of 
genotype 1b sequences), KLSSLGLNAV (18.4 %), which predominantly circulates in 
Europe, KLSALGLNAV (12.5 %) and KLSALGVNAV (4.3 %), which predominantly 
circulates in Japan, as well as a unique epitope sequence (QLSGLGINAV) originating 
from a large single-source outbreak (Wiese et al 2000). In addition, a well described 
genotype 1a sequence and its variant were studied (prototype: KLVALGINAV, 
43.3 % and variant: KLVALGVNAV, 31.3 %). 
Several studies indicated that HLA-binding shape CD8+ T cell immunodominance 
(Kotturi et al 2008, Sette et al 1994). Analysis of the peptide-binding to HLA-A*02 
revealed that all seven variants show equally high binding affinity (see figure 4.7) and 
therefore did not have any impact on priming capacity in this study.  
 
After expansion for 28 days, the presence of variant-specific CD8+ T cells was 
analyzed by dextramer staining (see figure 4.8A). There were substantial differences 
in the priming capacities of the different epitope variants. Interestingly, the variant 
that is mainly circulating in Japan NS31406-1415 KLSALGLNAV showed the best 
priming potential in comparison to the other variants. Furthermore, this epitope 
variant elicited functional effector CD8+ T cells by means of IFN-γ production (see 
figure 4.8B). Moreover, CD8+ T cells primed with the KLSALGLNAV variant were 
polyfunctional with respect to the secretion of effector cytokines and chemokines, i.e. 
TNF-α, MIP-1β, IL-2, IFN-γ and the expression of the degranulation marker CD107a. 
Almost ¾ of KLSALGLNAV-specific CD8+ T cells were able to produce more than 
three effector molecules. Several studies suggest that effective vaccination should 
induce robust CD4+ and CD8+ T cell responses for long-term immunity (Cooper et al 
1999, Gruner et al 2000, Lechner et al 2000). In addition, vaccination has to 
overcome the enormous viral sequence variation and therefore has to induce a 
broad, polyfunctional and cross-reactive immune response, capable to respond to 
viral sequence variants. Analysis of the cross-reactivity of the peptide-specific CD8+ 
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T cells revealed a high degree of cross- reactivity for KLSALGLNAV-primed CD8+ T 
cells (see figure 4.10).  
Immune resposes are initiated via T cell receptors that make contact to peptide-MHC 
complexes. The TCR consists of four polypeptides (α, β, γ, δ) that merge to two 
forms of heterodimers (αβ and γδ). Each polypeptide has a variable (V), joining (J) 
and constant (C) region. TCR diversity is generated upon rearrangement of this 
regions. Additional diversity is mediated by the random insertion of non-germline-
encoded nucleotides at the junctions of these rearranged segments, which provides 
the main site of antigen recognition (Rubtsova et al 2009). Several methods to 
analyze T cell receptor repertoires are available, including the TCR-variable segment 
analysis by implementation of a comprehensive antibody panel directed against 
individual TCR Vβ chains. Vβ chain analysis defines whether a peptide-specific T cell 
response is polyclonal or dominated by a few TCR clonotypes. In the present study, 
the TCR Vβ chain repertoire was analyzed in NS31406-1415 QLSGLGINAV-primed 
CD8+ T cells (good priming capacity, no cross-reactivity) and compared to NS31406-
1415 KLSALGLNAV-primed CD8+ T cells (very good priming capacity, good cross-
reactivity), using an antibody panel. Analysis of the individual Vβ chains showed a 
clear difference in profiles of TCR Vβ bias. CD8+ IFN-γ+ T cells primed with the 
KLSALGLNAV-variant were characterized by a broader TCR Vβ use (see figure 4.13 
panel A, black bars), whereas CD8+ IFN-γ+ T cells primed with the QLSGLGINAV 
variant that were characterized by a more restricted use of TCR Vβ chains (see 
figure 4.13, panel B and C, blue bars). Importantly, upon restimulation with other 
epitope variants the same Vβ chains as for the homologous variant were utilized (see 
figure 4.13, red bars) suggesting that the individual Vβ were cross-reactive. It is 
unclear, if cross-reactivity upon priming with the KLSALGLNAV-variant was defined 
at the TCR clonotype level or if a complex mixture of multiple clonotypes with distinct 
fine specificities was primed. To address this in more detail, TCR clonotype analysis 
by cloning of individual TCR would be required. Of note, prior studies suggest that 
the number of individual TCR expressed on CD8+ T cells is essential in determining 
the fine specificity and effector functions in antigen-specific CD8+ T cells (Lim et al 
2000). Thus, usage of multiple Vβ chains as observed upon priming with the 
KLSALGLNAV-variant strongly suggests a benefit for the CD8+ T cells. 
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In the present study, PBMC isolated from HLA-A*02 positive buffy coats from healthy 
volunteer blood donors were used. HLA-typing revealed that all patients had the 
HLA-A*02:01 allelic variant (data not shown). Among the HLA-A*02 allelic variants 
HLA-A*02:01 is the most prevalent variant, hence commonly used to study HLA-
A*02-restricted CD8+ T cell responses. HLA-A*02 allelic variants are unevenly 
distributed worldwide, with certain alleles predominating among different ethnicities. 
HLA-A*02:01 is predominantly present in the Caucasian and Native American 
population, with almost >90 % of HLA-A*02 positive carrying this allelic variant. In 
contrast, in the Japanese population, only 47 % of the HLA-A*02 population express 
this allelic variant and 36 % carry HLA-A*02:06 (Chen et al 2012). Evidence suggests 
that polymorphisms in the peptide-binding groove affect binding of peptide-antigens 
(Matsui et al 1994) and thus influences the repertoire of peptides presented by this 
allelic variant. Taking this into account, the blood donors used in this study are 
somewhat biased towards the Caucasian allelic variant. It can be hypothesized that 
the results of the priming capacity for the different variants of the present study (see 
figure 4.8) is influenced by this allelic restriction. Studying the epitope variants in the 
context of other allelic variants, e.g. HLA-A*02:06, might influence the outcome 
significantly and has to be taken into consideration.  
 
HCV is characterized by high levels of genetic variation between genotypes and 
subtypes but also between isolates of the same subtype. In the context of HLA-allelic 
restriction, this high sequence diversity thus represents the main barrier for immune 
control. There is strong evidence that the protective effect of certain HLA alleles on 
infection outcome is limited to certain HCV genotypes. Studies indicate that the 
protective effect of HLA class I alleles can be abrogated due to sequence differences 
between genotypes (Giugliano et al 2009, Neumann-Haefelin et al 2010) indicating 
that sequence differences are relevant at the epitope level. Evidence suggests that 
transmission of viral strains with pre-existing mutations in immunodominant epitopes 
attenuates viral control and epitope variants that are less recognized abrogate 
protective effects (Kim et al 2011). In line with that we could recently show that pre-
existing substitutions in the infection source influence the impact of corresponding 
HLA alleles. In two large HCV genotype 1b outbreaks, from the late ‘70s in Ireland 
and the former German Democratic Republic, conflicting results have been observed 
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concerning the effect of particular HLA class I alleles on disease outcome. We 
compared sequences in immunodominant CD8+ T cell epitopes from the infection 
source of both cohorts and the consequences for immune selection pressure and 
viral evolution in the East-German cohort. We found that sequence differences in key 
epitopes in the infection source between the Irish and the East-German cohort have 
profound effects on the ability to clear HCV infection in the presence of particular 
HLA class I alleles (Ziegler et al 2013). 
Taken together, these findings show that even minor sequence variations in the 
same subtype can abrogate CD8+ T cell responses, which is of great importance in 
choosing suitable sequences for vaccine design. 
 
Over the last decades numerous vaccine approaches have been assessed, including 
those that have focused on inducing T cell responses to the non-structural HCV 
antigens. NS antigens are genetically more conserved compared to envelope 
proteins and were shown to contain multiple CD4+ and CD8+ T cell epitopes. Four 
main strategies to induce T cell responses upon vaccination have been studied in 
humans so far. These include recombinant protein vaccines, peptide vaccines, DNA 
vaccines and vector vaccines [reviewed in (Halliday et al 2011)]. Peptide vaccines 
are well tolerated, however, peptide vaccines are restricted to defined epitopes and 
may not cover the whole variety of HLA alleles, although the number of epitopes 
required to achieve immune control remains elusive for HCV. If only a few epitopes 
are included in a vaccine, T cell response to individual epitopes may be maximized, 
but there is the risk that the induced immune response is insufficient to control the 
virus, e.g. because the genetic barrier to escape is too low. The therapeutic peptide 
vaccine IC41 contains five synthetic peptides from core, NS3 and NS4 proteins 
combined with the adjuvant poly-l-arginine (Klade et al 2008). Biweekly IC41 
administration was found to induce T cell responses in chronically HCV infected 
patients (Firbas et al 2010), but there was no impact on viral load. In contrast to this 
peptide approach, mosaic vaccines contain fragments of natural sequences, which 
were assembled using an algorithmic approach to maximize the coverage of potential 
T cell epitopes (Yusim et al 2010). This approach may theoretically be beneficial to 
allow T cell priming against the majority of circulating viral variants, though, the huge 
antigen diversity in a vaccine may also be disadvantageous when the T cell response 
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is biased towards irrelevant epitopes. Both extremes in ongoing vaccine research 
show that the seemingly simple task to select an antigen for vaccination is rather 
complex and not defined yet for HCV. It is clearly important to induce broad and 
polyfunctional CD8+ T cell responses covering the genetic diversity of circulating 
isolates, as well as infecting quasispecies. The data obtained in this thesis suggest 
that it may be necessary to address this experimentally for individual epitopes. 
Importantly, in contrast to our expectation, the optimal epitope sequence for priming 
of a CD8+ T cell against the predominant sequence in Europe was not this European 
sequence itself. We could show that a Japanese sequence (KLSALGLNAV) rarely 
observed in Europe showed the highest priming capacity and induced CD8+ T cells 
that were cross-reactive even with European sequences. This has important 
consequences for vaccine design against variable pathogens. The data imply that 
superior antigen sequences for activation of T cells may exist and that these “optimal” 
antigens are not necessarily the most frequent in circulating variants of the pathogen. 
In fact, it is possible that the “optimal” antigen sequence is even absent from 
circulating pathogen variants, which makes selection of the optimal antigen sequence 
for vaccine design rather difficult. 
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5.2 PHH inhibit the expansion of virus-specific CD8+ T cells 
One possible mechanism that might explain the impaired immune responses in HCV 
infection represents the site of primary T cell activation, which in HCV infection 
occurs in the liver. In fact, the liver displays distinct immunological properties, as 
primary T cell activation in the liver frequently results in immunological tolerance. This 
advantage in settings of tolerance induction to liver grafts, but is detrimental to 
immune responses generated against HCV. In this study, we analyzed the influence 
of primary human hepatocytes (PHH) on the expansion of virus-specific CD8+ T 
cells. We could show that PHH inhibit the expansion of CD8+ T cells in a contact 
depended manner, which was accompanied by increased levels of TGF-β. 
 
5.2.1 Role of hepatocytes on primary intrahepatic T cell activation 
Hepatocytes comprises 70-80 % of hepatic cells (Wick et al 2002) and are thus the 
main cell type in the liver. Hepatocytes are involved in the regulation of metabolisms, 
including detoxification and processing of lipids, amino acids and proteins. In early 
HCV infection, hepatocytes are the predominant liver cell expressing HCV antigens 
to virus-specific T cells. Studies by Warren and colleagues showed that circulating 
naïve CD8+ T cells and hepatocytes occur, although it was long thought to be 
impossible due to physical separation (Warren et al 2006). In this study, we show that 
primary human hepatocytes inhibit the expansion of CMV- or Flu-specific CD8+ T 
cells in a contact depended manner (see figure 4.17). Former studies in mice models 
already indicated that purified hepatocytes are able to activate naïve CD8+ T cells in 
vitro, even in the absence of costimulatory molecules. The induced proliferation was 
comparable in magnitude to that seen in response to DC stimulation, but in contrast 
to CD8+ T cells activated by splenocytes, hepatocyte activated CD8+ T cells lost 
their proliferative capacity after 3 days of co-culture (Bertolino et al 1998). Similar to 
that, in vivo studies of mice indicated that activation of CD8+ T cells by antigen-
bearing hepatocytes lead to the premature death, which was assigned to limited IL-2 
production and low expression of the antiapoptotic bcl-xL and bcl-2 survival genes. In 
addition, T cell activation by hepatocytes resulted in the upregulation of the 
proapoptotic proteins Bim and caspase 3, which triggers apoptosis of those cells 
(Holz et al 2010). Premature death could be prevented by supplying exogenous IL-2 
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or by providing CD28 co-stimulation, suggesting that the failure of hepatocytes to 
express CD28 ligands may have been responsible for premature death of activated 
CD8+ T cells (Bertolino et al 1999). In the present study, PHH/ PBMC were 
repeatedly fed with exogenous IL-2, which could not overcome the hepatocyte 
mediated inhibition.  
 
Recently it has been shown that hepatocytes up-regulate PD-L1 upon viral infections. 
PD-L1 is the ligand for the co-inhibitory molecule PD-1, which is additionally 
upregulated on HCV-specific CD8+ T cells (Golden-Mason et al 2007, Penna et al 
2007, Radziewicz et al 2007) (see 1.4.2.2). Blocking the physical contact of co-
inhibitory molecules by the insertion of a transwell in the co-culture system, might 
explain the reversion of the inhibition in the transwell setting (see figure 4.17C). This 
was additionally confirmed by medium transfer experiments. Soluble factors play only 
a minor role in this setting, as the transfer of conditioned medium did only mediate 
minor inhibitory effects, which can be explained by the exhaustion of nutrients.  
 
5.2.2 Role of TGF-β in PHH/ PBMC co-cultures 
One main factor despite liver-resident APC in the induction of tolerance is the local 
presence of immunoregulatory mediators IL-10, PGE2 and TGF-β. These 
immunosuppressive mediators are secreted by various cell types, including LSEC, 
Kupffer cells and hepatocytes (Bissell et al 1995, Knolle et al 1995, Rieder et al 
1990). To verify the influence of potential proinflammatory or inhibitory cytokines in 
the present study, the cytokine profile in the supernatant was analyzed (see figures 
4.18 and 4.19). We could not detect any increase in IL-10 (see figure 4.18) nor in 
PGE2 concentrations (data not shown). Importantly, increased concentrations of 
TGF-β were detectable in PHH/ PBMC co-cultures (see figure 4.19). In this setting, 
regulatory T cells might play a role. It was shown that CD4+ CD25- naïve T cells are 
converted to CD4+ CD25+ regulatory T cells by TGF-β-mediated induction of the 
transcription factor Foxp3 (Chen et al 2003). CD4+ CD25+ regulatory T cells have 
emerged as a unique population of suppressor cells that mediate peripheral 
tolerance (Sakaguchi 2000, Shevach 2002). Evidence suggest that compared with 
normal livers, the livers of HCV or HBV infected patients contain increased numbers 
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of Foxp3-positive regulatory T cells, which suppress effector T cells (Franceschini et 
al 2009, Manigold and Racanelli 2007). Unfortunately, we were not able to block the 
mode of action of TGF-β in this setting and could thus not confirm a role of TGF- β. 
Studies in mice models performed in collaboration with Jia Liu at the institute of 
virology in Essen supported the role of TGF-β-mediated suppression. These data 
confirmed on the one hand that the hepatocyte mediated inhibition is contact-
dependent (figure 5.1A and B), as the production of pro-inflammatory cytokines IL-2, 
TNF-α and IFN-γ is reconstituted in transwell experiments (figure 5.1B, blue edge), 
but also shows that neutralization of TGF-β using an anti-TGF-β neutralizing antibody 
can restore splenocyte proliferation (Jia Liu et al 2012, unpublished data).  
 
 
Figure 5.1 Primary murine hepatocytes (PMH) inhibit the proliferation of splenocytes (SC) in a 
contact-dependent manner. 
(A) SC were isolated and incubated with anti-CD3/ CD28 antibodies in the presence or absence of PMH and anti-
TGF-β. (B) The cytokine profile of contact-dependent or independent (blue edge) PMH/ SC co-cultures was 
analyzed after 72 hours by ELISA (Jia Liu et al 2012, unpublished data). 
 
Long-term culture of primary hepatocytes is a challenging task, as primary 
hepatocytes rapidly lose their cuboidal morphology and liver-specific functions over a 
few days of culture. The cells accumulate actin stress fibers and become fibroblast-
like. One common technique to culture primary hepatocytes is to seed the cells on a 
single layer of collagen gel. Under these conditions, hepatocytes keep liver-specific 
functions for a short period, notwithstanding, liver-specific functions decline within the 
first week (Shulman and Nahmias 2013).  
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Primary human hepatocytes are mainly isolated from fibrotic livers, hepatocellular 
carcinomas or those rejected from transplantation (see appendix and figure 4.14) 
resulting in a huge variability in quality. Indeed, human hepatocytes are isolated in 
most cases from diseased livers, which results in differences in the isolation 
procedure, as well as the quality of PHH, leading to variations concerning the purity 
of the hepatocyte culture. Furthermore, PHH are very rarely available, which lead to a 
limitation in experimental recapitulation. In contrast to that primary murine 
hepatocytes are available in a physiological, as well as genetically more defined 
background. Thus, primary murine hepatocyte cultures are in contrast to human 
hepatocytes better reproducible, which might explain the differences obtained 
between the primary human and murine hepatocyte cultures. In addition, technical 
differences between the isolation procedure of murine and human hepatocytes might 
influence the purity of primary hepatocyte cultures. 
 
Bowen and colleagues discussed a two-site model of T cell activation, which suggest 
that the site of initial antigen encounter by CD8+ T cells determines the outcome of 
an immune response mounted in the liver. If the majority of T cells are activated in 
the liver in contrast to the lymph nodes, tolerance will occur. Effective immune 
responses would than require that the majority of antigen-specific cells are activated 
in the lymph nodes (Bowen et al 2005). In early HCV infection, HCV-specific antigen 
presentation to resident lymphocytes occurs solely in the liver and might thus 
represent a mechanism of the failure of the host immune response to hepatotropic 
viral infections. 
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6 Summary 
Infection with the hepatitis C virus still remains a global health problem. The antiviral 
immune response against HCV by CD8+ T cells plays a central role in viral 
containment, however, it has been highlighted in numerous studies that the CD8+ T 
cell responses during HCV infection are relatively weak and dysfunctional. Activation 
of virus-specific CD8+ T cells is a multi-step process, in which the sequence of the 
presented antigen, as well as the site of antigen presentation has important 
consequences for the quality of the CD8+ T cell response. Hence, in the present 
thesis, determinants of HCV-specific CD8+ T cell expansion were analyzed. 
 
HCV is characterized by high levels of genetic variation between genotypes and 
subtypes but also between isolates of the same subtype. This high sequence 
variation in immunodominant epitopes precludes protective immunity and represents 
a major obstacle to vaccine design. 
In this study, we analyzed the global sequence diversity of the immunodominant 
HLA-A*02-restricted CD8+ T cell epitope NS31406-1415 in circulating genotype 1a and 
1b isolates and its impact on CD8+ T cell priming and induction of cross-reactive T 
cell responses. Circulating sequence variants of the NS31406-1415 epitope showed 
distinct priming potential and cross-reactivity patterns. Importantly, the highest 
degree of cross-reactivity was induced by a sequence that is rarely observed in the 
European population. Upon vaccination, the elicited CD8+ T cells should be 
polyfunctional and target multiple epitope variants. This study highlights the 
relevance of antigen sequence variation for subsequent CD8+ T cell responses and 
provides a rational for the selection of the optimal epitope sequence for a vaccine 
against HCV, associated with the induction of a broad cross-reactive and 
polyfunctional CD8+ T cell response. 
 
A hallmark of chronic infections with hepatotropic viruses such as HCV is the 
notoriously weak antiviral immune response by CD8+ T cells. Primary antigen 
encounter in HCV infections happens in the liver. It is believed that the liver-specific 
environment can induce tolerance either by induction of dysfunctional CD8+ T cells 
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or by premature death of activated CD8+ T cells. Recent reports from mouse models 
indicate that hepatocytes can act as antigen-presenting. Direct antigen presentation 
by virally infected hepatocytes thus might inhibit the CD8+ T cell response. 
This study showed that the frequency of virus-specific CD8+ T cells after 10 days 
expansion was dramatically reduced in the presence of hepatocytes. This 
suppressive effect was independent of the cell-type that was used for antigen-
presentation (hepatocyte or PBMC) and of antigen-specific contact. Expansion of 
CD8+ T cells in the presence of hepatocytes was almost completely restored in 
transwell experiments indicating that the suppressive effect is cell-contact dependent. 
Analysis of the cytokine profile from culture supernatants revealed increased 
concentrations of TGF-β in the presence of hepatocytes compared to their absence.  
This study gives important hints for the establishment of chronic infections by 
hepatotropic viruses. 
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7 Zusammenfassung 
Infektionen mit dem Hepatitis C Virus (HCV) sind global ein enormes Problem. 
Verschiedene Studien belegen, dass während einer akuten HCV-Infektion CD8+ T 
Zellen eine wichtige Rolle bei der Kontrolle der Virusinfektion spielen. Allerdings sind 
HCV-spezifische T Zellantworten oft schwach und dysfunktional. Die Aktivierung 
virusspezifischer T Zellen ist ein sensitiver, komplexer Prozess, bei dem sowohl die 
Sequenz des präsentierten Antigens, als auch das Umfeld in dem der primäre 
Kontakt zwischen antigenpräsentierender und virusspezifischer Zelle stattfindet, 
Einfluss auf die resultierende T Zellantwort ausübt. Daher wurden in der vorliegenden 
Studie Faktoren der HCV-spezifischen T Zellantwort untersucht.  
 
Das Hepatitis C Virus zeichnet sich durch ein hohes Maß an genetischer Variabilität 
aus. Es werden sieben verschiedene Genotypen und multiple Subtypen 
unterschieden, aber selbst zwischen Varianten des gleichen Subtyps gibt es wichtige 
Sequenzunterschiede. Diese hohe Sequenzvariabilität ist ein entscheidendes 
Hindernis in der Entwicklung eines geeigneten Impfstoffs gegen HCV. Allerdings wird 
selbst nach spontaner Ausheilung einer Infektion eine protektive Immunantwort 
häufig nicht erreicht, da sich immundominante Epitope zwischen verschiedenen HCV 
Isolaten unterscheiden und diese Sequenzvarianten häufig nicht von CD8+ T Zellen 
erkannt werden.  
Im ersten Teil dieser Arbeit wurde die globale Sequenzdiversität der Genotypen 1a 
und 1b in einem immundominanten HLA-A*02-assoziierten CD8+ T Zell-Epitop 
NS31406-1415 analysiert. Dabei wurde der Einfluss der Sequenzunterschiede auf die 
‚Priming‘-Kapazität von CD8+ T Zellen sowie die Induktion von kreuzreaktiven CD8+ 
T Zellen untersucht. Es konnte gezeigt werden, dass sich die global zirkulierenden 
Varianten in ihrer ‚Priming‘-Kapazität von CD8+ T Zellen unterscheiden. Diese in vitro 
generierten T Zellantworten unterschieden sich maßgeblich in ihrer Fähigkeit der 
Kreuzreaktivität. Interessanterweise stammt die Sequenzvariante mit der breitesten 
Kreuzreaktivität aus Isolaten, die hauptsächlich in Japan zirkulieren und somit nur 
selten in Europa zu finden sind. Ein Impfstoff gegen HCV sollte eine polyfunktionelle 
CD8+ T Zellantwort hervorrufen und ebenso kreuzreaktiv mit Sequenzvarianten des 
Epitops sein. In dieser Studie konnte die entscheidende Bedeutung von Sequenz-
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variationen in einem Antigen für die folgende CD8+ T Zellantwort gezeigt werden. 
Die Daten unterstreichen, wie wichtig die Auswahl der optimalen Epitopsequenz für 
eine Vakzine gegen HCV ist, indem eine polyfunktionelle sowie auch kreuzreaktive 
CD8+ T Zellantwort aktiviert wird. 
 
Im Falle einer Infektion mit dem Hepatitis C Virus findet der erste Kontakt zwischen 
antigenpräsentierender und virusspezifischer Zelle in der Leber statt. Die Leber spielt 
eine wichtige Rolle im adaptiven Immunsystem, da hier die Präsentation von 
Antigenen an CD8+ T Zellen Toleranz induzieren kann, indem dysfunktionale CD8+ 
T Zellen induziert werden oder deren Aktivierung in der Leber zu früher Apoptose 
führt. Ein Kennzeichen chronischer Infektion mit hepatotropen Viren ist somit die 
schwache Immunantwort durch CD8+ T Zellen. Jüngere Studien an Mausmodellen 
konnten belegen, dass Hepatozyten ebenfalls als antigenpräsentierende Zellen 
fungieren und demnach möglicherweise eine Rolle in der Toleranzinduktion von 
CD8+ T Zellen einnehmen.  
Im zweiten Teil der vorliegenden Arbeit wurde gezeigt, dass die Expansion virus-
spezifischer CD8+ T Zellen in der Anwesenheit von primären humanen Hepatozyten 
drastisch reduziert ist. Die Hemmung der virusspezifischen CD8+ T Zellexpansion 
war unabhängig vom antigenpräsentierenden Zelltyp und war unabhängig vom 
antigenspezifischen Kontakt. Die Hemmung der virusspezifischen CD8+ T Zell 
Expansion war allerdings aufgehoben, wenn direkter Kontakt zwischen Hepatozyten 
und PBMC durch den Gebrauch eines Membraneinsatzes in der Kultur verhindert 
wurde. Dies deutet an, dass der hemmende Effekt von Hepatozyten kontaktabhängig 
ist. Eine Analyse der Zellkulturüberstände erwies eine erhöhte Konzentration von 
TGF-β in der Anwesenheit von Hepatozyten.  
In der vorliegenden Studie wurde demnach gezeigt, dass eine Hemmung der CD8+ T 
Zellantwort durch Hepatozyten möglicherweise zur Chronifizierung von Infektionen 
mit hepatotropen Viren beitragen kann. 
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10 Appendix 
Table 10.1 Patient data. 
# Gender Age Disease Surgery 
1 w 78 liver metastasis Resection 
2 w 29 healthy donor donation 
3 m 60 hepatocellular carcinoma resection 
4 w 60 metastasis resection 
5 m 68 HCV, hepatocellular carcinoma LTX 
6 m 60 HCV infection LTX 
7 w 41 Adenoma resection 
8 w 49 HCV infection resection 
9 m 48 HCV infection LTX 
10 w 28 Healthy resection 
11 w 61 HCV infection LTX 
12 m 50 HCV infection LTX 
13 w 69 bile duct carcinoma resection 
14 m 63 HBV infection LTX 
15 w 57 Carcinoma resection 
16 m 58 hepatocellular carcinoma LTX 
17 m 50 HBV,hepatocellular carcinoma LTX 
18 w 38 Nonalcoholic Steatohepatitis resection 
19 w 39 
acute liver failure due to bei Budd-
Chiari syndrome LTX 
20 m 47 Primary sclerosing cholangitis LTX 
21 m 77 cholangiocellular carcinoma resection 
22 m 32 Metastasis resection 
23 m 53 HCV infection LTX 
24 m 60 hepatocellular carcinoma resection 
25 m 81 Klatskin Tumor resection 
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11 Abbreviations 
α   anti 
7-AAD  7-Aminoactinomycin D 
ALK-5   Activin receptor-like kinase-5 
APC   Allophycocyanin 
APC   Antigen-presenting cell 
ARFP   Alternative reading frame protein 
approx  approximately 
BCL-2   B cell lymphoma-2 
Bim   BCL-2-interacting mediatior of death 
C   Constant 
C   Cytosine 
°C   Degree celsius 
CD   Cluster of differentiation 
CLDN   Claudin 
CMV   Cytomegalovirus 
CO2   Carbon dioxide 
C-terminal  Carboxy terminal 
CTLA-4  Cytotoxic T lymphocyte associated antigen-4 
Cy   Cyanine 
DAA   Direct acting antivirals 
DC   Dendritic cell 
DC-SIGN Dendritic cell-specific intracellular adhesion molecule-3-grabbin 
non-integrin 
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DMEM  Dulbecco’s Modified Eagles’ Medium  
DMSO  Dimethyl sulfoxide 
DNA   Desoxyribonucleic acid 
EBV   Epstein-Barr Virus 
EDTA   Ethylenediaminetetraacetic acid  
e.g.   for example (lat. exempli gratia) 
ELISA   Enzyme-linked immunosorbent assay 
ER   Endoplasmatic reticulum 
et al   and others (lat. et alii) 
FACS   Fluorescence activated cell sorting 
FBS   Fetal bovine serum 
FITC   Fluorescein isothiocyanate 
FSC   Forward scatter 
g   Gram 
g (x g)   Gravity; times gravity 
GAG   Glycosaminoglycanes 
GM-CSF  Granulocyte macrophage colony-stimulating factor 
Gy   Gray 
h   Hour 
HBV   Hepatitis B virus  
HCC   Hepatocellular carcinoma 
HCV   Hepatitis C virus 
HCVcc  Hepatitis C virus cell culture system 
HCVpp  Hepatitis C virus pseudo particle 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Abbreviations 
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HIV   Human immunodeficiency virus 
HLA   Human leukocyte antigen 
HS   Human serum 
HUVEC  Human umbilical vein endothelial cells 
HVR   Hypervariable region 
IC   Intracellular 
ICS   Intracellular cytokine staining 
IDU   Injection drug user 
i.e.   that is (lat. id est) 
IFN   Interferon 
IL   Interleukine 
IPS   IFN-β-promotor stimulator protein-I 
IRES   Internal ribosomal entry site 
IRF-3   Interferon-regulatory factor-3 
ISG   Interferon-stimulated genes 
IU   International units 
J   Joining 
kb   Kilo base 
KIR   Killer immunoglobulin-like receptor 
L   Liter  
LPS   Lipopolysaccharide 
LSEC   Liver sinusoidal endothelial cells 
L-SIGN Liver/ lymph node-specific intracellular adhesion molecule-3-
grabbin non-integrin 
LTX Liver transplantation 
Abbreviations 
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M   Molar 
μ   Micro 
m   Milli 
MACS  Magnetic cell separation 
MAVS   Mitochondrial antiviral signaling molecule 
mDC   Myeloid dendritic cells 
MFI   Mean fluorescent intensity 
MHC   Major Histocompatibility Complex 
MIP-1β  Macrophage inflammatory protein -1beta 
moDC   Monocyte-derived dendritic cell 
NF-κB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
NK   Natural killer cell 
NKT   Natural killer T cell 
n(m)   Nano(meter) 
NS   Non-structural 
n.s.   not significant 
N-terminal  amino terminal 
OCLDN  Occludin 
ORF   Open reading frame 
p   Pico 
PAMP   Pathogen-associated molecular patterns 
PBMC  Peripheral blood mononuclear cells 
PBS   Phosphate-buffered saline 
PCR   Polymerase chain reaction 
PD-1   Programmed cell death-1 
Abbreviations 
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pDC   Plasmacytoid dendritic cells 
PE   Phycoerythrin 
peg   Pegylated 
PerCP   Peridinin chlorophyll protein  
PET   Polyethylene terephthalate 
PHH   Primary human hepatocytes 
PMH   Primary murine hepatocytes 
PP2AC  Protein phosphatase 2AC 
PGE2   Prostaglandin E2 
PRR   Pattern recognition receptors 
rh   Recombinant human 
RIG-I   Retinoic acid-inducible gene-I 
RNA   Ribonucleic acid  
RPMI   Roswell Park Memorial Institute 
RT   Room temperature 
SC   Splenocytes 
SSC   sideward scatter 
SOC3   Suppressor of cytokine signaling 3  
SR-B1  Scavenger receptor class B type 1 
SVR   Sustained virological response 
T   Thymine 
TAP   Transporter associated with antigen processing 
TCR   T cell receptor 
TGF   Transforming growth factor 
Tim-3   T cell immunoglobulin domain and mucin domain protein-3 
Abbreviations 
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TLR   Toll-like receptors 
TNF   Tumor necrosis factor 
TRIF   TIR domain-containing adapter-inducting interferon-β 
U   Unit  
UTR   Untranslated region 
UV   Ultra violet 
V   Variable 
(V)LDL  (very)-low-density lipoprotein receptor 
vs.   towards (lat. versus) 
WHO   The World Health Organization 
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